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CHAPTER 1 NICOTINE USE DISORDER
1.1 Public Health Significance
Tobacco use, especially cigarette smoking, is a significant public health problem.
Tobacco use is the leading cause of preventable death in the United States (US;
480,000+ deaths per year) (U.S. Department of Health and Human Services, 2014).
Approximately one of every five deaths in the US each year are associated with
tobacco use (U.S. Department of Health and Human Services, 2014). In addition to
severe health consequences, cigarette smoking costs the US economy $300+ billion
per year in lost productivity and medical expenses (U.S. Department of Health and
Human Services, 2014). Approximately 57 million people (aged 12+ yrs) in the US
currently smoke cigarettes (SAMHSA, 2011). However, encouragingly, ~70% of current
smokers report a desire to quit (SAMHSA, 2011).
1.2 Pharmacotherapy
The

most

efficacious

Food

and

Drug

pharmacotherapies for smoking cessation are:

Administration

(FDA)-indicated

nicotine replacement products (e.g.

nicotine gum, lozenges, and transdermal patches), varenicline (α4β2 nicotinic
acetylcholine receptor partial agonist), and bupropion (aminoketone antidepressant)
(Eisenberg et al., 2008; Etter & Stapleton, 2006; Gonzales et al., 2006; Jorenby et al.,
1999; Lancaster, Stead, Silagy, & Sowden, 2000; Mills et al., 2012; Silagy, Lancaster,
Stead, Mant, & Fowler, 2005; Ucar et al., 2014). These medications attenuated
cigarette craving and nicotine withdrawal symptoms, and improved short-term
abstinence rates, relative to placebo (Eisenberg et al., 2008; Etter & Stapleton, 2006;
Gonzales et al., 2006; Jorenby et al., 1999; Lancaster et al., 2000; Mills et al., 2012;
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Silagy et al., 2005; Ucar et al., 2014). However, meta-analyses of treatment studies
indicated smoking abstinence rates at 6- and 12-month follow-ups were unacceptably
low (14-36% and 13-28%, respectively) (Eisenberg et al., 2008; Etter & Stapleton,
2006; Gonzales et al., 2006; Jorenby et al., 1999; Nides et al., 2008; Silagy et al., 2005;
Ucar et al., 2014). Despite effective attenuation of nicotine craving and withdrawal
symptoms, the majority of smokers relapsed within the first year of treatment on these
medications. This begs the question: what other factors precipitate smoking relapse,
and are not attenuated by these medications? One such factor is stress. Historically,
stress has been defined as physiological responses to demands placed upon the body
(Selye, 1936, 1973). In this study, stress is defined by the acute physiological
responses (e.g. elevated heart rate, blood pressure, breathing rate etc.) that are
typically associated with stressful events (for a more complete description see below).
1.3 Stress and Smoking Relapse
Treatment research studies indicated stress was among the most commonly
cited precipitants to smoking relapse (M. al'Absi, 2006; Heishman, 1999; Hymowitz,
Sexton, Ockene, & Grandits, 1991; Matheny & Weatherman, 1998). One study found
that more than 60% of cigarette smokers attributed their relapse to stress (Hughes,
2009). Moreover, individuals who reported high stress levels during abstinence were
more likely to relapse (Brewer, Catalano, Haggerty, Gainey, & Fleming, 1998; S. Cohen
& Lichtenstein, 1990).
Stressful

events

activate

the

Autonomic

Nervous

System

(ANS)

and

Hypothalamus-Pituitary-Adrenal (HPA) axis which can increase heart rate, blood
pressure, breathing rate, and levels of circulating noradrenaline and cortisol (among
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other physiological effects) (Mustafa al'Absi, 2006; G. F. Koob, 2008; Pocock, Richards,
& Richards, 2013; Sinha, Garcia, Paliwal, Kreek, & Rounsaville, 2006). Activation of the
sympathetic branch of the ANS (associated with noradrenaline release) prepares an
individual for immediate action (so-called ‘fight or flight’ response) (Pocock et al., 2013).
The HPA axis response (associated with cortisol release) is slower and less predictable,
but has important biological effects (Dickerson & Kemeny, 2004). Acute nicotine
administration can activate, and chronic nicotine administration can dysregulate, ANS
and HPA axis responses (Picciotto, Brunzell, & Caldarone, 2002). Nicotine is a central
nervous system stimulant; acute administration is associated with increased blood
pressure, heart rate, and plasma noradrenaline and corticosteroid levels (Brazell,
Mitchell, & Gray, 1991; Cryer, Haymond, Santiago, & Shah, 1976; Picciotto et al.,
2002). Chronic nicotine exposure was associated with elevated levels of noradrenaline
and cortisol during active use and acute abstinence, and dysregulated physiological
reactivity to experimental stress-induction (Andersson, Eneroth, Fuxe, Mascagni, &
Agnati, 1985; Childs & De Wit, 2009; C Kirschbaum, Wüst, & Strasburger, 1992; G. F.
Koob, 2008; George F. Koob & Moal, 1997; Kreek & Koob, 1998; Picciotto et al., 2002;
Tsuda, Steptoe, West, Fieldman, & Kirschbaum, 1996; Wilkins et al., 1982). Thus, longterm cigarette smoking may dysregulate the stress system, which in turn, may increase
the likelihood of relapse.
FDA-indicated pharmacotherapies were not designed to, and do not, attenuate
stress-induced biobehavioral reactions. Ray et al. (2013) demonstrated that varenicline
decreased basal cigarette craving and blocked cigarette cue-induced craving, but not
cue- plus stress-induced cigarette craving (Ray et al., 2013). During acute smoking
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abstinence, bupropion was associated with increased physiological indices of stress
reactivity at rest and following an experimental stress-induction task (Kotlyar et al.,
2006). Acute nicotine administration (e.g. nicotine replacement products) among
chronic smokers can attenuate HPA axis response to experimental stress-induction
(Childs & De Wit, 2009; Rohleder & Kirschbaum, 2006), but may increase
cardiovascular output (heart rate and blood pressure) (Perkins, Epstein, Jennings, &
Stiller, 1986). Moreover, chronic nicotine use is associated with overactive HPA axis
and ANS systems (Andersson et al., 1985; G. F. Koob, 2008; George F Koob & Le
Moal, 1997).
1.4 Adjunctive Medications
The effectiveness of existing pharmacotherapies may be enhanced by adjunctive
medications that attenuate an individual’s physiological response to stress. In a
preclinical study, prazosin (α1-adrenoreceptor antagonist) attenuated the effects of
pharmacological stress-induction on alcohol seeking behavior (A. Le et al., 2011). In
humans, prazosin blunted the effects of psychosocial stress-induction on blood
pressure, alcohol craving, anxiety, and negative emotion among alcohol dependent
individuals during outpatient treatment (Helen C Fox et al., 2012). Similarly, guanfacine
(α2-adrenoreceptor agonist) attenuated stress- and drug cue-induced craving and
anxiety among cocaine-dependent individuals (H. C. Fox et al., 2012). These
preliminary

studies

suggest

that

supplementing

existing

FDA-indicating

pharmacotherapies with stress-blunting medications may improve smoking cessation
rates. Indeed, an ongoing clinical trial is investigating the efficacy of combined
varenicline + prazosin on smoking cessation (results not yet available).
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1.5 Summary
The goal of this section was to briefly introduce the public health problem and
research focus of this study. A review of all smoking cessation treatments (e.g.
cognitive and behavioral interventions) was beyond the scope of this section and would
not further clarify the concepts presented herein.
In summary, nicotine use, especially chronic cigarette smoking, is a significant
public health problem. FDA-indicated pharmacotherapies for smoking cessation are
associated with dismal long-term abstinence rates. One plausible explanation is that
existing pharmacotherapies do not attenuate the deleterious effects of acute stress.
There is ample non-experimental evidence linking stress to smoking relapse. In the next
chapter, I will review the evidence that acute experimental stress potentiated substance
use and reinstatement (model of relapse). In addition, I will review the literature on brain
regions associated with substance use disorders and the impact of acute experimental
stress on brain function. Finally, I will describe the dissertation study design, aims, and
hypotheses.
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CHAPTER 2 EXPERIMENTAL STRESS EFFECTS
2.1 Preclinical Models of Substance Use Relapse
The reinstatement model of preclinical substance use relapse is widely used and
has good criterion and construct validity (Epstein, Preston, Stewart, & Shaham, 2006).
The specific parameters of the reinstatement model vary across studies, but generally
include the following: acquisition (initial drug self-administration), maintenance (regular
drug self-administration), extinction (protracted abstinence), experimental challenge,
and reinstatement (relapse) (Shaham, Shalev, Lu, de Wit, & Stewart, 2003). During the
acquisition phase, the animal is able to earn units of drug via behavioral responding.
Drug-seeking behavior is operationalized as behavioral responding (e.g. nose poke,
pressing a lever) that resulted in drug administration. Drug-seeking behavior is a direct
behavioral measure of appetitive drug motivation with translational validity in human
experimental research. During the maintenance phase, the animal is able to earn units
of drug via behavioral responding during predefined time periods until drug taking
reaches a plateau and has stabilized. This phase is a proxy of chronic substance use.
During the extinction phase, behavioral responding no longer results in receipt of drug
(e.g. saline is substituted). Behavioral responding will gradually decrease until cessation
(i.e. drug-seeking behavior was extinguished). Finally, the animal is challenged with an
experimental manipulation (e.g. stress, drug-paired cue, or drug priming dose). If the
animal exhibits behavioral responding on the drug-associated option, drug-seeking
behavior has been reinstated (i.e. the animal is said to have relapsed).
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2.2 Preclinical Experimental Stress Manipulation
A variety of preclinical experimental stress manipulations exist, including:
predator scent, foot shock, restraint, and pharmacological agents. Pharmacological
agents have methodological advantages over other approaches: neurochemical
specificity, methodological control, and translational potential. Preclinical models of
relapse demonstrated that pharmacological stress agents (that mimic ANS and HPA
axis responses) reinstated drug-seeking and self-administration across drugs of abuse
(Epstein et al., 2006; Feltenstein, Ghee, & See, 2012; Le, Harding, Juzytsch, Funk, &
Shaham, 2005; Mantsch & Katz, 2007; Mantsch et al., 2014; Mantsch et al., 2010;
Shaham, Erb, & Stewart, 2000; Shaham et al., 2003; Shaham & Stewart, 1995).
Yohimbine (YOH) is an α2-adrenoreceptor antagonist that increases noradrenergic
levels (i.e. sympathetic ANS response to stressful events) by blocking the presynaptic
autoreceptor (Doxey, Lane, Roach, & Virdce, 1984; Goldberg & Robertson, 1983).
Acute YOH administration reinstated behavioral responding (i.e. YOH precipitated
relapse) for cocaine, methamphetamine, alcohol, and nicotine in rodents (Ahmed &
Koob, 1997; Buczek, Le, Wang, Stewart, & Shaham, 1999; Erb et al., 2000; Erb,
Shaham, & Stewart, 1996; Gass & Olive, 2007; Le et al., 2005; Mantsch & Katz, 2007;
Mantsch et al., 2014; Mantsch et al., 2010; Shepard, Bossert, Liu, & Shaham, 2004).
YOH reliably produced anxiogenic effects in rodents and humans (Charney, Heninger,
& Redmond Jr, 1983; A. D. Le et al., 2011; Pellow, Johnston, & File, 1987; Stine et al.,
2002). YOH increased biomarkers of a physiological stress response: systolic and
diastolic blood pressure and saliva α-amylase (Ehlert, Erni, Hebisch, & Nater, 2006;
Greenwald, Lundahl, & Steinmiller, 2013; Murburg, Villacres, Ko, & Veith, 1991; Stine et
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al., 2002). Glucocorticoid and mineralocorticoid receptor agonists (corticosterone
[rodents] and cortisol [humans]) modulated the effect of YOH on drug-seeking behavior
(de Jong, Steenbergen, & de Kloet, 2009; Deroche, Marinelli, Le Moal, & Piazza, 1997;
Graf et al., 2013; Mantsch & Katz, 2007; Mantsch et al., 2014). In combination, they
simulate a robust physiological stress response (both ANS and HPA axis) and reliably
reinstate drug-seeking behavior in preclinical models of substance use relapse.
2.3 Human Experimental Stress Manipulation
Human experimental studies often use psychosocial stress-induction techniques,
including: guided imagery, mental arithmetic, or public speaking (Dedovic, D'Aguiar, &
Pruessner, 2009; Dickerson & Kemeny, 2004). Psychosocial stress-induction
manipulations have non-trivial limitations, including: lack of placebo-control (possible
expectancy effects); no dose manipulation (inability to control stressor intensity); and
unreliable and brief physiological stress response (<30min) (Dickerson & Kemeny,
2004; Greenwald et al., 2013).
Pharmacological

stress-induction

has

methodological

advantages

over

psychosocial approaches and reverse-translational validity with preclinical studies.
Pharmacological agents that mimic the endogenous HPA axis and ANS stress
response (e.g. YOH in combination with a glucocorticoid and mineralocorticoid receptor
agonist)

provide

a

powerful

model

of

acute

experimental

stress-induction.

Hydrocortisone (HYD) is a glucocorticoid and mineralocorticoid receptor agonist with
good bioavailability that reliably increases plasma and saliva cortisol levels in humans
(Meikle & Tyler, 1977). Together, YOH+HYD: a) mimic ANS- and HPA axis-mediated
stress responses (increase the primary stress hormones: noradrenaline and cortisol);
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b) produce reliable, sustained, and dose-dependent physiological stress responses;
and c) enable double-blind, placebo-controlled administration (de Jong et al., 2009;
Deroche et al., 1997; Graf et al., 2013; Mantsch & Katz, 2007; Mantsch et al., 2014).
Our laboratory recently investigated the effects of oral pretreatment of YOH
alone and YOH+HYD in non-treatment-seeking, opioid-dependent volunteers. The
primary outcome variable was opioid-seeking behavior. Human experimental stress
studies often measure proxies of substance use (e.g. craving) or infer statistical
relationships to future substance use. In contrast to those approaches, drug-seeking
behavior is a direct measure of appetitive drug motivation that results in drug
administration. Participants in our recent lab study were able to earn (via computer
‘mouse’ clicking) units of hydromorphone (μ opioid receptor agonist) or money on a
choice progressive ratio task. Response requirements (number of mouse clicks)
increased with each successive unit earned (independently for both drug and money).
Immediately after the task, earned units of hydromorphone were administered
(intramuscular injection). Thus, appetitive opioid motivation (number of opioid units
earned) was measured in the absence of acute drug effects (e.g. disinhibition or
satiation). Findings indicated YOH alone (Greenwald et al., 2013) and YOH+HYD
(Greenwald et al., in preparation) increased opioid (hydromorphone) seeking behavior
in sublingual buprenorphine-maintained (8mg/day) heroin-dependent individuals. In
addition, oral pretreatment with YOH 54mg + HYD 20mg (similar to doses proposed in
this study) produced statistically-significant, but clinically-safe, increases in blood
pressure (both systolic and diastolic) and saliva cortisol that lasted for approximately
three hours. These findings demonstrated that oral pretreatment with YOH+HYD is a
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robust pharmacological stress-induction technique that potentiated drug-seeking
behavior among opioid-dependent individuals. Together with the preclinical literature,
there is substantial evidence that experimental stress-induction reliably increases drugseeking behavior. However, the neurobiological pathways through which stress
potentiates drug-seeking behavior remain unclear.
2.4 Substance Use and Brain Function
2.4.1 Top-down vs. Bottom-up
Neuroimaging studies provide insight into brain regions and networks associated
with substance use. Broadly speaking, brain regions associated with drug cue
appraisal, appetitive motivation, and decision making can be divided into two networks:
top-down and bottom-up (Bechara, 2005; Nestor, McCabe, Jones, Clancy, & Garavan,
2011). The top-down network is often conceptualized as the ‘brake pedal’ to the
bottom-up ‘gas pedal’. Bottom-up signals are associated with appetitive drug
motivation, craving, and withdrawal/negative affect. Top-down network structures
modulate bottom-up signals, and are associated with executive function, planning, and
goal-directed behaviors. Substance use-related decision making (e.g. whether or not to
use a drug at a particular moment) is thought to arise from these competing signals
(Rangel, Camerer, & Montague, 2008).
2.4.2 Bottom-up Network
Dopaminergic signaling in the ventral striatum (including the nucleus accumbens
[NAcc]) mediates acute drug reinforcement (Di Chiara & Imperato, 1988). Following
repeated substance use, drug-paired visual cues become conditioned stimuli and elicit
dopamine release in the NAcc (in the absence of substance administration), consistent
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with appetitive craving (N. Volkow, Fowler, Wang, Baler, & Telang, 2009; N. D. Volkow
et al., 2006, 2008). Substance use disorders are associated with enhanced salience
attribution to drug-related visual cues (Rita Z Goldstein & Volkow, 2002; R. Z. Goldstein
& Volkow, 2011). Visual drug cue evoked blood oxygen level-dependent (BOLD)
activation measured via functional magnetic resonance imaging (fMRI) is often robust,
but patterns vary across studies and are influenced by several methodological factors
(Jasinska, Stein, Kaiser, Naumer, & Yalachkov, 2014), such as treatment status (out-oftreatment individuals show more robust activation), time since last cigarette (acute
abstinence enhanced cue reactivity), and temporal delay until next smoking opportunity
(immediate smoking opportunities are associated with more robust activation) (Jasinska
et al., 2014; Wilson, Sayette, Delgado, & Fiez, 2005). Meta-analyses of fMRI studies
indicated that consistently activated regions included: the medial orbitofrontal cortex
(mOFC), medial prefrontal cortex (mPFC), ventral striatum (including NAcc), and dorsal
striatum (Chase, Eickhoff, Laird, & Hogarth, 2011; Engelmann et al., 2012; Kühn &
Gallinat, 2011; Wilson, Sayette, & Fiez, 2004)). BOLD activation in the mPFC and
mOFC is thought to reflect drug cue appraisal and/or salience (Chase et al., 2011;
Hayashi, Ko, Strafella, & Dagher, 2013; Wilson et al., 2004). The two most consistently
activated regions are the amygdala and the ventral striatum (e.g. NAcc) (Chase et al.,
2011; Engelmann et al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Activation in
the amygdala may reflect the emotional salience of the visual drug cue presented
(Chase et al., 2011; Engelmann et al., 2012; Kühn & Gallinat, 2011; Wilson et al.,
2004). The ventral striatum is associated with craving and appetitive motivation, and is
part of the ‘final common pathway’ of addiction (Rita Z Goldstein & Volkow, 2002; P. W.
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Kalivas, Volkow, & Seamans, 2005; G. F. Koob & Volkow, 2010; N. Volkow et al.,
2009). Collectively, activation in bottom-up ‘reward’ network structures is associated
with drug cue salience, craving, and appetitive motivation.
2.4.3 Top-down Network
Top-down (frontal-to-striatal) network function is important for many cognitive
processes, including: attention, decision making, and goal-directed behavior (Rita Z
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011; Rangel et al., 2008). Topdown network function emanates from the dorsolateral prefrontal cortex (dlPFC) (Rita Z
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011). Substance abuse is
associated with structural and functional changes. Relative to matched controls,
cigarette smokers exhibited reduced gray matter volume in dlPFC and ventrolateral
PFC (vlPFC) (Brody et al., 2004). Chronic substance use is associated with impaired
dlPFC-dependent non-drug-specific cognitive processes (attentional control, decision
making, and impulse inhibition) (Banich, 2009; R. Z. Goldstein & Volkow, 2011). In
addition, the dlPFC is involved in drug use-related cognitive processes: self-control,
delayed gratification, drug cue reactivity, and response inhibition (Hare, Camerer, &
Rangel, 2009; Hare, Hakimi, & Rangel, 2014; Nestor et al., 2011; Wilson et al., 2004).
Smoking cue appraisal was associated with attenuated dlPFC, and exaggerated
striatal, activation in current smokers, compared to ex-smokers (Nestor et al., 2011).
Moreover, response inhibition (associated with PFC activation (Aron & Poldrack, 2006;
Chikazoe et al., 2009)) was impaired in cigarette smokers, relative to controls (Luijten,
Littel, & Franken, 2011; Powell, Dawkins, & Davis, 2002). Activation in the dlPFC was
positively correlated with selection of delayed monetary rewards (delayed gratification)
(Figner et al., 2010; Hare et al., 2014; Luo, Ainslie, Pollini, Giragosian, & Monterosso,
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2012; McClure, Ericson, Laibson, Loewenstein, & Cohen, 2007; McClure, Laibson,
Loewenstein, & Cohen, 2004). Repetitive transcranial magnetic stimulation (rTMS) is a
non-invasive technique capable of temporally potentiating (pulse frequency ≥ 5Hz) or
inhibiting (< 1Hz) neural activity (Leo & Latif, 2007). rTMS delivers a series of magnetic
pulses that pass through the skull and modulate electrical potential in the brain (usually
not deeper than the cortex) (Leo & Latif, 2007). rTMS-induced temporary ‘functional
lesions’ indicated that left (and not right) dlPFC function was associated with selection
of delayed rewards (Figner et al., 2010). Moreover, rTMS-induced ‘functional lesion’ of
the left dlPFC attenuated the potentiating effect of an immediate (vs. delayed) smoking
opportunity on cigarette craving (Hayashi et al., 2013). Collectively, these studies
illustrated the critical role of the dlPFC (and top-down executive control) in cognitive
processes (e.g. self-control, delayed gratification, and drug cue appraisal) associated
with substance use. Further, impaired dlPFC function (and associated cognitive
processes) may be an important factor that (temporally) precedes substance use
relapse.
2.5 Stress, Drugs, and Brain Function
2.5.1 Stress and Brain Function
The effects of acute experimental stress on brain function have been widely
studied in the learning and memory literature (more so than the substance use
literature). Review of this literature was useful for identifying the neural substrates of
experimental stress-induction. The specific effects of experimental stress on memory
vary depending on the stress manipulation and the type of memory investigated.
However, broadly speaking, experimental stress tends to impair prefrontal-dependent,
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and enhance striatal-dependent, cognitive processes. It should be noted there is a rich
literature of the effects of chronic stress on brain function, but discussion of those
findings are beyond the scope of this dissertation study.
In a series of studies, Schwabe and colleagues examined the effects of
pretreatment with pharmacological stress-inducing agents (self-administration of oral
YOH and HYD) on instrumental learning behavior (L. Schwabe, Joels, Roozendaal,
Wolf, & Oitzl, 2012; L. Schwabe, Tegenthoff, Hoffken, & Wolf, 2010, 2012; L. Schwabe
& Wolf, 2011; Lars Schwabe & Wolf, 2013)). Results demonstrated that YOH+HYD, but
not YOH or HYD alone, rendered participant behavior insensitive to outcome
devaluation (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L. Schwabe
& Wolf, 2011). The authors interpreted these data to indicate that participants
responded habitually and YOH+HYD impaired ‘goal-directed’ behavior during the task.
Preclinical lesion and human neuroimaging studies indicated that goal-directed
behavior is dlPFC-dependent (Bernard W Balleine & Dickinson, 1998; B. W. Balleine &
O'Doherty, 2010; Corbit & Balleine, 2003; Valentin, Dickinson, & O'Doherty, 2007)
whereas habit-directed responding is associated with the dorsal striatum (Tricomi,
Balleine, & O’Doherty, 2009; Yin & Knowlton, 2006; Yin, Knowlton, & Balleine, 2004;
Yin, Ostlund, Knowlton, & Balleine, 2005). YOH+HYD reduced the sensitivity of
mOFC/mPFC to changes in outcome value, whereas the dorsal striatum was
unaffected (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L. Schwabe
& Wolf, 2011). Thus, during YOH+HYD, the outcome devaluation signal (encoded by
mOFC/mPFC) failed to shift behavior (i.e. to goal-directed responding; dlPFC) during
task performance (L. Schwabe et al., 2010; L. Schwabe, Tegenthoff, et al., 2012; L.
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Schwabe & Wolf, 2011). In the context of substance use, acute stress may shift an
individual’s behavior from goal-directed (e.g. maintaining abstinence) to habit-directed
(stimulus-response; e.g. cue elicited smoking relapse). Acute stress may increase the
likelihood of substance use relapse via impaired dlPFC function. As described above,
dlPFC function is associated with cognitive processes essential for maintenance of
substance use abstinence (e.g. self-control, delayed gratification, and goal-directed
behavior).
A widely studied cognitive function associated with the dlPFC function is working
memory. Working memory is the active maintenance and neural representation of
information over a brief delay period (typically 2-10 sec) prior to recall. A meta-analysis
of fMRI studies indicated that working memory task performance (N-back; described in
Section 3.2.8) was consistently associated with dlPFC and vlPFC activation (Owen,
McMillan, Laird, & Bullmore, 2005). Importantly, the N-back working memory task is
versatile and can be administered with or without drug-related stimuli (e.g. smoking
images). One study found that psychosocial stress-induction attenuated dlPFC
activation during a neutral N-back task performance and impaired response accuracy in
healthy control subjects (Qin, Hermans, van Marle, Luo, & Fernández, 2009).
In non-human primates, spatial working memory has been studied. Primates
were trained to retain the spatial location of a visual cue and respond via saccade (eye
movement) following a brief delay period (typically 2-10 sec) (Goldman-Rakic, 1995).
Electrodes implanted in the primate dlPFC indicated that spiking frequency increased
during the delay period (time period between stimulus presentation and recall).
Researchers concluded that feedforward microcircuits in the dlPFC (cortical layer III)
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maintained a neural representation of the cue during the delay period, such that the
primate was able to respond accurately (A. F. Arnsten, Wang, & Paspalas, 2012;
Goldman-Rakic, 1995; Wang et al., 2013). Follow-up studies indicated that local, and
systemic, administration of NMDA receptor antagonists attenuated neural spiking
activity in the dlPFC and impaired response accuracy (Honey et al., 2004; Krystal et al.,
2005; Wang et al., 2013). These well-controlled studies provided compelling evidence
that working memory performance was mediated via neural spiking activity –
specifically, glutamatergic neurotransmission binding post-synaptic NMDA receptors –
in the dlPFC.
Non-human primate working memory performance (using the same experimental
paradigm) exhibited an inverted “U” relationship with noradrenaline levels (A. F.
Arnsten, 2009). Abnormally low (e.g. fatigue) (A. Arnsten & Goldman-Rakic, 1985) and
high levels of noradrenaline (e.g. stress or YOH dose) (A. F. Arnsten, Mathew, Ubriani,
Taylor, & Li, 1999; S. Birnbaum, Gobeske, Auerbach, Taylor, & Arnsten, 1999; S. G.
Birnbaum et al., 2004; Doxey et al., 1984; Ramos et al., 2005) impaired working
memory task performance (A. F. Arnsten, 2009). Optimal working memory performance
(during alert and non-stressed conditions) was associated with moderate noradrenaline
levels, and predominantly, α2A-adrenoreceptor stimulation (A. Arnsten & GoldmanRakic, 1985; Li & Mei, 1994). High levels of noradrenaline stimulated the lower affinity
α1- and β1-adrenoreceptors (S. Birnbaum et al., 1999; Ramos et al., 2005), suppressed
dlPFC neuronal spiking activity (Li, Mao, Wang, & Mei, 1999; Wang et al., 2007), and
impaired response accuracy (A. F. Arnsten et al., 1999; S. G. Birnbaum et al., 2004).
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In summary, a widely studied dlPFC-dependent cognitive process is working
memory. Experimental stress (or administration of its neurochemical substrates: i.e.
noradrenaline) attenuated dlPFC working memory task engagement (BOLD and neural
spiking frequency) and impaired response accuracy. In addition, pharmacological
stress-induction was associated with impaired ‘goal-directed’ behavior (dlPFCdependent). Collectively, these studies provide support for the hypothesis that acute
stress may increase the likelihood of substance use relapse via attenuated dlPFC
engagement and impaired function.
2.5.2 Stress, Drugs, and Brain Function
The effects of acute experimental stress on substance use-related cognitive
processes are not well understood. Research in this area has been limited by the
experimental approaches used. As described above, with few exceptions, prior
research studies used psychosocial stress manipulations. Psychosocial stress
manipulations are associated with unreliable and short-lived (<30min) physiological
stress responses that hinder their utility in neuroimaging investigations. Perhaps most
limiting, psychosocial stressors are inherently dependent on cognitive processing to
induce a physiological stress response. The BOLD response associated with the stressinducing task will confound network activation changes associated with the
physiological stress response (i.e. elevated cortisol and noradrenaline). These
limitations and varied psychosocial stress-induction methodology have contributed to an
inconsistent, and sometimes conflicting, neuroimaging literature (Dedovic et al., 2009).
Despite these limitations, several effects have been reliably observed across studies
and are described below.
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Experimental stress-induction

(in

the

absence

of

drug cues or drug

administration) reliably increased dopaminergic neurotransmission in the NAcc in
preclinical and clinical studies (Abercrombie, Keefe, DiFrischia, & Zigmond, 1989;
Imperato, Angelucci, Casolini, Zocchi, & Puglisi-Allegra, 1992; Pruessner, Champagne,
Meaney, & Dagher, 2004; Rougé-Pont, Piazza, Kharouby, Le Moal, & Simon, 1993). As
described above, increased dopaminergic signaling in the NAcc is consistent with the
reinforcing effects of acute drug administration (G. F. Koob & Volkow, 2010). Thus,
acute stress may elicit appetitive craving in absence of drug cues or administration (i.e.
stress may amplify ‘bottom-up’ signals). In addition, fMRI studies indicated that acute
psychosocial stressors altered neural network activation and increased drug craving in
the absence of drug cues (Sinha, 2001; Sinha, 2009; Sinha et al., 2006; Sinha & Li,
2007). Despite similar levels of subjective distress during a guided imagery stressinducing technique, cocaine-dependent individuals exhibited greater BOLD activation in
the caudate and dorsal striatum, and less activation in the parahippocampal gyrus,
hippocampus, fusiform and anterior cingulate, compared to drug-naive controls (Sinha
et al., 2005). In a related study (using the same stress-induction technique), increased
BOLD activation in the mPFC during stress predicted shorter time to relapse during a
90-day post-treatment follow-up period (Sinha & Li, 2007).
To date, no clinical neuroimaging studies (to the knowledge of the author) have
examined the potentially additive effects of concurrent experimental stress-induction
and drug cue appraisal. Two studies examined the effects of sequential stress-induction
and visual drug cue exposure during BOLD fMRI (Dagher, Tannenbaum, Hayashi,
Pruessner, & McBride, 2009; Potenza et al., 2012). However, both studies used
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psychosocial stress-induction techniques that may have confounded the physiological
stress effects on visual drug cue appraisal and resultant BOLD activation. Moreover,
physiological stress response biomarkers were not consistently measured. One study
did not measure cortisol or noradrenaline levels (Potenza et al., 2012), whereas the
other reported non-significant stress effects on saliva cortisol (Dagher et al., 2009).
Moreover, neither study measured blood pressure (Dagher et al., 2009; Potenza et al.,
2012). Thus, it remains unclear whether experimental stress-induction alters neural
network response to visual drug cues.

Figure 1.1: Proposed Mechanisms of Action. The conceptual guiding hypothesis and
proposed mechanisms of action are illustrated. Acute stress may potentiate drug-seeking
behavior via impaired top-down executive function (specifically, dlPFC function) and/or
enhanced bottom-up signals (aversive internal states, cue salience, drug craving, or
withdrawal symptoms).
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2.6 Study Aims and Hypotheses
2.6.1 Conceptual Overview
Conceptually, the guiding hypothesis of this project is that stress potentiates
drug-seeking and self-administration by altering frontostriatal network function (with the
dlPFC acting as a fulcrum) to: 1) disrupt homeostasis; 2) mediate aversive internal
states; 3) enhance smoking cue salience and appetitive motivation; and 4) attenuate
dlPFC task engagement and impair dlPFC function (Figure 1.1). Our approach aligns
with Goldstein & Volkow’s conceptualization of substance use disorders (impaired
response inhibition and salience attribution; iRISA), and with Koob’s theory that chronic
substance use causes neural counter-adaptations that dysregulate motivation and
induce sensitization to stressors (Rita Z Goldstein & Volkow, 2002; R. Z. Goldstein &
Volkow, 2011; G. F. Koob, 2008, 2009, 2010; George F. Koob & Moal, 1997).
2.6.2 Neurobiological Mechanism
The central aim of this study was to investigate a plausible neurobiological
mechanism for stress-potentiated drug-seeking behavior. This study used a
pharmacological stress-induction approach (oral pretreatment with YOH 54mg + HYD
10mg). Combined oral pretreatment with YOH+HYD offers a powerful stress-induction
approach that activates both HPA and ANS stress systems. We hypothesized that
acute experimental stress would attenuate dlPFC engagement and impair response
accuracy on a dlPFC-dependent cognitive task. Impaired dlPFC function is a plausible
neurobiological mechanism through which acute stress may potentiate nicotine selfadministration. A multimodal neuroimaging approach (in vivo functional proton magnetic
resonance spectroscopy [1H fMRS] and BOLD fMRI) was used to examine dlPFC
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engagement and function during letter N-back task performance. There is widespread
support indicating this neurobiological mechanism is plausible (described in detail
above), but has not been directly tested in any published studies (known to the author).
2.6.3 Study Aims and Hypotheses
Brief study overview. Chronic, regular cigarette smokers were recruited locally
and screened for participation. Participants completed two identical experimental
sessions under double-blind, placebo-controlled and within-subject randomized crossover oral-dosing conditions: active (YOH 54mg + HYD 10mg) and placebo (YOH 0mg +
HYD 0mg) stress. Throughout each session, subjective and physiological stress effects
were assessed periodically. Participants completed a 60min MRI scan (which included
1

H fMRS and BOLD fMRI). Finally, nicotine-seeking and self-administration behavior

was measured via a choice, progressive ratio task. Nicotine-seeking and selfadministration directly measure nicotine motivation. This experimental design isolated
the effects of pharmacological stress-induction on stress response biomarkers,
subjective internal states, dlPFC function and task engagement, and nicotine-seeking
and self-administration among non-treatment-seeking cigarette smokers.
Aim 1: Assess the effects of YOH+HYD on physiologic stress response
biomarkers and subjective internal states. Hypotheses: 1a) Relative to placebo (0mg +
0mg), oral pretreatment with YOH+HYD (54mg + 10mg) will significantly increase blood
pressure (systolic and diastolic), saliva cortisol and α-amylase. Prior research in our
laboratory indicated that comparable oral pretreatment doses of YOH+HYD elicited a
robust physiological stress response among buprenorphine-maintained, opioiddependent individuals (Greenwald et al., in preparation). 1b) Relative to placebo,
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YOH+HYD will significantly increase self-reported anxiety, negative affect, nicotine
withdrawal symptom severity, and relief-motivated nicotine craving, but will not alter
positive affect or appetitive craving. Prior research indicated that acute stressors can
induce aversive internal states (M. al'Absi, 2006; al'Absi, Hatsukami, & Davis, 2005;
Kalman, 2002; Swan, Ward, & Jack, 1996). Exploratory hypothesis: 1c) Relative to
placebo, YOH+HYD will produce a physiologic stress response (e.g. heart rate, blood
pressure, and saliva cortisol) comparable in magnitude to robust psychosocial stressors
(i.e. qualitative comparison of effect sizes from the literature).
Aim 2: Investigate the effect of YOH+HYD on nicotine-seeking and selfadministration among non-treatment-seeking current cigarette smokers. Hypotheses:
2a) Relative to placebo, YOH+HYD will potentiate nicotine-seeking and selfadministration behavior (more cigarette puffs earned during the choice progressive ratio
task and smoked during the self-administration phase). Prior research in our laboratory
(Section 3.2.10) demonstrated that oral pretreatment with YOH+HYD increased opioidseeking among buprenorphine-maintained, opioid-dependent individuals (Greenwald et
al., in preparation). Exploratory hypothesis: 2b) YOH+HYD will not alter nicotine
consumption rate (i.e. inter-puff intervals).
Aim 3: Investigate 1H fMRS glutamate (GLU) modulation in the dlPFC during
working memory task performance. Hypotheses: 3a) Relative to fixation cross rest, 2back task performance will be associated with higher GLU levels during placebo. Prior
research indicated that 2-back task performance was associated with robust BOLD
activation bilaterally in the dlPFC (Owen et al., 2005) and fMRI BOLD activation was colocated with elevated GLU levels (measured via

1

H fMRS) (Mangia et al., 2006;
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Schaller, Mekle, Xin, Kunz, & Gruetter, 2013; Schaller, Xin, O'Brien, Magill, & Gruetter,
2014). GLU modulation is an in vivo biomarker of neural activation (or taskengagement) that may reflect increased metabolic activity (Mangia et al., 2006; Schaller
et al., 2013; Schaller et al., 2014). Importantly, GLU modulation is not confounded by
vasoactive pharmaceutical agents (e.g. YOH). 3b) During YOH+HYD, 2-back GLU
levels will not differ from fixation cross rest GLU levels. 3c) 2-back response accuracy
will be higher during placebo, relative to YOH+HYD. Prior research in working memory
task performance indicated that acute stress (e.g. YOH+HYD) attenuated dlPFC
engagement (BOLD and neural spiking frequency) and impaired response accuracy (A.
F. Arnsten, 2009; Qin et al., 2009).
Aim 4: Investigate BOLD activation changes associated with YOH+HYD during
smoking (> neutral) cued N-back fMRI task. Hypotheses: 4a) Relative to placebo,
YOH+HYD will enhance BOLD activation in the mPFC, mOFC, ventral and dorsal
striatum during smoking cue (> neutral) images across N-back task levels (0-, 1-, and 2back). These hypotheses are consistent with published literature; YOH+HYD will
increase mOFC/mPFC activation (consistent with (Sinha & Li, 2007)), and decrease
activation of the Amg (consistent with (Dagher et al., 2009)) and dlPFC (consistent with
(Qin et al., 2009)). 4b) During 2-back task performance, smoking cued images will be
associated with higher response accuracy, relative to neutral images, during both
experimental sessions. Consistent with the iRISA theory (Rita Z Goldstein & Volkow,
2002; R. Z. Goldstein & Volkow, 2011), attentional bias toward drug-related stimuli will
facilitate more accurate responding for smoking cued images, relative to neutral

24

images. 4c) Response accuracy will not differ by image type during 0- or 1-back task
performance during either experimental session (ceiling effect anticipated).

25

CHAPTER 3 MATERIALS AND METHODS
3.1 1H fMRS Pilot Study
3.1.1 Study Overview
Prior 1H fMRS research has demonstrated significant GLU modulation in the
occipital cortex (during visual stimulation) (Mangia et al., 2006; Schaller et al., 2013)
and motor cortex (during a finger tapping task) (Schaller et al., 2014). Our group
recently extended this approach to cognitive task performance and replicated this effect
in the hippocampus (during hippocampal-dependent cognitive task performance)
(Jeffrey A Stanley et al., 2017). However, 1H fMRS measurement of in vivo GLU
modulation in the dlPFC during working memory task performance is novel. Therefore,
a pilot study was conducted to develop a 1H fMRS working memory task paradigm and
evaluate the effect of task performance on GLU levels in the dlPFC.
3.1.2 Participant Recruitment
The Wayne State University Institutional Review Board (WSU IRB) approved all
study procedures, which were conducted in accordance with the Declaration of Helsinki
(1964). Healthy right-hand dominant male and female volunteers (aged 18-30 years)
who reported no MRI contraindications, psychiatric diagnoses, or psychoactive
medications were recruited from the Detroit metropolitan area. Interested individuals
completed a brief screening procedure to verify eligibility. Participants deemed eligible
provided informed consent and were compensated $50 for their time.
3.1.3 Experimental Protocol
Participants (N = 16) completed self-report measures (medication history,
demographic questionnaire, and contact information), a comprehensive MRI safety
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screen with an MRI technologist (~5 min), and a MRI scan (~60 min) during a single
experimental session. Each participant received verbal instructions and completed
several practice runs of the letter 2-back task outside of the magnet (until deemed
proficient by the experimenter), prior to the MRI scan. Experimental tasks were
programmed using Presentation software (version 18.1) and displayed on-screen inside
the MRI scanner via projection system. Participants were able to communicate with the
MR technologist via speaker/microphone system inside the scanner.
Each MRI scan consisted of a structural image, left dlPFC B0-field shimming,
voxel placement, and two 1H fMRS experimental tasks (Figure 3.1): continuous fixationcross rest and letter 2-back. Participants were verbally instructed to relax, focus their
gaze on the fixation-cross, and let their thoughts drift during continuous fixation-cross
rest. On screen, participants were prompted to “Rest” (2s) followed by a static,
continuous fixation-cross (238s; centered on screen). The letter 2-back working
memory task consisted of two phases: flashing grayscale checkerboard (3Hz; 208s)
and seven blocks of alternating periods of fixation-cross rest (32s) and letter 2-back
(64s). Prior research in our laboratory demonstrated that the flashing checkerboard
minimized the variability in the GLU signal prior to investigation of task-related
modulation (Lynn et al., in preparation). Participants were instructed to relax, focus their
gaze on screen, and let their thoughts drift during the flashing checkerboard and
interleaved fixation-cross rest. Every period of interleaved fixation-cross rest was
prompted on screen with “Rest” (2s) prior to static fixation-cross (30s). Similarly, every
letter 2-back task block was prompted with “2-back” (4s) followed by serial presentation
of 20 capitalized letters (3s/letter; 6 target letters; letters displayed for 500ms followed
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Figure 3.1: 1H fMRS Pilot Study Experimental Paradigm. The continuous fixation cross rest
(left) consisted of instructions (‘Rest,’ 2s) followed by continuous, static fixation cross (238s).
The letter 2-back task (right) consisted of two phases: flashing checkerboard (3Hz, 208s)
and seven repetitions of letter 2-back (64s; instructions ‘2-back’ [4s], 20 letters [3s/letter;
60s]) with interleaved fixation cross rest (instructions ‘Rest’ [2s] and static fixation cross rest
by[30s]).
2500ms of blank screen). Subjects indicated (via button press) if the letter on screen

matched the letter presented two previously. Participants were not provided feedback
about response accuracy. Response accuracy was quantified as a percentage of
correct responses for each task block.
3.1.4 Neuroimaging Parameters
All imaging was conducted on a 3 Tesla Siemens Verio system with 32-channel
receive-only head coil. All participant scans were completed in the morning between
9:00-11:30am. High resolution T1-weighted structural scans were collected using the 3D
Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence with the following
parameters: TR = 2.2s, TE = 3ms, TI = 799ms, flip angle = 13°, Field-of-View (FOV) =
256 x 256 x 160mm, 256 x 1mm thick axial slices, matrix = 176 x 256. Prior to 1H fMRS
acquisition, a region of the left dlPFC (2.5 x 2.5 x 2.5cm) larger than 1H fMRS voxel was
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shimmed to improve B0-field homogeneity (FASTESTMAP). 1H fMRS spectra were
continuously acquired every 16s (PRESS with OVS and VAPOR, TE = 23ms, TR =
4.0s, 4 averages/spectrum, bandwidth = 2 kHz, 2048 data points, no apodization)
during the continuous fixation-cross task (15 spectra, 240s) and letter 2-back (55
spectra, 880s). 1H fMRS spectra were acquired without water suppression immediately
after each task (TE = 23ms, TR = 10s, 2 averages/spectrum, bandwidth = 2 kHz, 2048
data points, no apodization). Unsuppressed water levels were used to scale metabolite
levels to absolute concentration values (mmol/kg wet weight).

Figure 3.2: 1H fMRS Pilot Study Voxel Placement. The 1H fMRS Pilot Study voxel (1.5 x 2.0
1.5 cm; 4.5 cm3) was located in the left dlPFC (Brodmann Areas 45 and 46).

3.1.5 Voxel Placement
1

3

H fMRS spectra were acquired from the left dlPFC (15 x 20 x 15 mm; 4.5 cm ;

Brodmann Areas 45 and 46; Figure 3.2). The voxel location was selected to encompass
regions consistently associated with significant BOLD activation in the dlPFC during
letter 2-back task performance (fMRI meta-analysis) (Owen et al., 2005). The
automated voxel placement (AVP) method (Woodcock, Arshad, Khatib, & Stanley,
2017) was used to prescribe 15 of 16 participant’s voxel locations (AVP not used for
one subject; experimenter error).

29

3.1.6 Automated Voxel Placement (AVP)
Single voxel MRS research studies often manually prescribe a voxel based on a
2D image of the current subject’s anatomy. Despite its widespread use, manual voxel
placement is time-consuming, challenging, and unreliable. This is especially
problematic for research studies, whose goal is often to investigate neurochemistry as a
function of psychiatric diagnosis (i.e. between-group research study) or treatment (i.e.
longitudinal study). Metabolite levels are known to vary across brain regions and by
voxel tissue composition (gray matter vs white matter vs cerebrospinal fluid). Therefore,
to avoid Type I or II error, voxel placement must be accurate and reliable across
research subjects and/or within a research subject across scans. AVP was developed
in response to the lack of reliable automated approaches for single voxel prescription.
The AVP suite consisted of three Linux- and Matlab-based scripts (Woodcock et
al., 2017). The first script, avp_create, facilitated creation of a library of template voxel
locations that were retained for future subject scans. The second script, avp_coregister,
facilitated accurate coregistration and prescription of a template voxel to each research
subject at the scanner (~2 min computer processing time) based on that subject’s T1weighted image (i.e. subject head position in the scanner). Figure 3.3 illustrates the
processing logic used in avp_create and avp_coregister. The third and final script,
avp_overlap, gathered information stored in the subject’s .rda file (ASCII file created
during MRS measurements), recreated the prescribed voxel, coregistered the voxel to
the template brain, and calculated 3D geometric voxel overlap accuracy and reliability
across subject scans. The AVP suite is available for download free-of-charge
(Woodcock et al., 2017).
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Figure 3.3: AVP Processing Logic. First, the user selects a template brain and enters
voxel parameters (dimensions, center coordinate, and rotation angles; ‘avp_create’).
The generated voxel is retained for future coregistration. Second, the user selects a
template voxel for coregistration to the current subject (‘avp_coregister’). The subject’s
structural image is coregistered to the template brain and two inversion matrices are
generated (DOF = 6 and 9). These matrices facilitate calculation of rotation angles and
voxel center coordinate (respectively) in subject space for voxel prescription.
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3.1.7 Analysis Strategy
1

H fMRS Analyses.

1

H fMRS spectra were analyzed using LCModel version 6.3

(Provencher, 2008). Post-processing and metabolite quantification steps were 100%
automated. Eddy current effects were corrected using the unsuppressed water signal
(Klose, 1990). T1-weighted structural images were B1-field corrected, the brain image
extracted, and segmented into partial volume maps of CSF, grey and white matter
using FreeSurfer and FSL tools (e.g. FLIRT, NU_CORRECT, BET and FAST) (Dale,
Fischl, & Sereno, 1999; Smith et al., 2004). Finally, tissue composition within the MRS
voxel and appropriate correction factors (e.g. T 1 and T2 relaxation) were used to
calculate absolute GLU concentration (mmol/kg wet weight) (J. A. Stanley, Drost,
Williamson, & Thompson, 1995). Raw spectra were phase- and shift-corrected prior to
quantification. Consecutive raw spectra (4 averages, 16s, no apodization or zero-filling)
were averaged which resulted in 32s temporal resolution (8 averages). GLU levels
during the first 32s and final 32s of 2-back task performance (2-back A and B,
respectively) were contrasted with fixation-cross rest GLU levels (continuous and
interleaved fixation-cross considered separately).
Shapiro-Wilk test of normality and skewness and kurtosis statistics were used to
evaluate variable distributions prior to outcome analyses. Whenever necessary,
extreme values were winsorized (extreme value replaced with nearest value) to
normalize distributions prior to outcome analyses. Repeated measures analyses of
variance (rmANOVA) were used to analyze behavioral and neurochemical data. Followup paired t-tests were used to clarify significant main effects. Mean metabolite levels
during 2-back task were contrasted with rest levels. The metabolite of interest for this
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study was GLU. However, other metabolites (NAA, Myo-Inositol, GPC+PC, and
PCr+Cr) were analyzed to determine the neurochemical specificity of working memory
task modulation. Voxel overlap was quantified using the avp_overlap script (included in
the AVP suite) (Woodcock et al., 2017). 3D geometric voxel overlap percentage was
calculated between each subject’s voxel and the template voxel (i.e. accuracy), and
voxel overlap across all subjects (i.e. reliability). Descriptive statistics are presented as
mean ± one standard deviation (M ± 1 SD) unless otherwise noted. In all figures, error
bars represent ± one standard error of the mean (SEM).
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3.2 Dissertation Study
3.2.1 Participant Recruitment
The WSU IRB approved all study procedures, which were conducted in
accordance with the Declaration of Helsinki (1964). Participants were recruited from the
Detroit metropolitan area via Craigslist advertisements. Interested individuals (> 500)
completed a brief (20min) standardized phone screen to rule out obvious study
contraindications. At the end of the phone screen, eligible individuals were provided an
overview of experimental procedures, including a description of pharmacological agents
(and possible side effects), MRI scan, and urine drug screen (UDS) procedure.
Interested individuals (105) were scheduled for a thorough in-person screen (2hr) at the
Human Pharmacology Laboratory (Tolan Park Medical Building, Suite 2A).
Upon arrival to the in-person screening appointment, participant sobriety was
verified (expired breath alcohol concentration: <.002%). Prior to obtaining participant
informed consent, a research assistant described the in-person interview procedures in
detail. Participants who provided written informed consent were eligible to complete the
remainder of the in-person screen which included: self-report measures (described in
the Self-Report Measures section below), brief (~20min) computerized psychiatric
interview, expired breath carbon monoxide measurement (CO; biomarker of recent
cigarette smoking), UDS (tested for substance use and pregnancy), electrocardiogram
(ECG), vital signs measurement (resting blood pressure, heart rate, blood oxygen
saturation), and MRI contraindications screen (self-report). A licensed cardiologist
evaluated the ECG. A complete description of inclusion and exclusion criteria is listed
below. Participants were compensated $20 for completion of the in-person screening
visit (independent of eligibility).
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3.2.2 Inclusion and Exclusion Criteria
Inclusion criteria:
1) Current smoker: expired breath CO ≥ 5ppm, self-reported 10+ cigarettes/day,
Fagerstrom Test of Nicotine Dependence (FTND) score ≥ 4
2) Aged 21-35 years: date of birth verification (driver’s license)
3) Sober at screening: negligible expired breath alcohol (<.002%)
4) Cardiovascular health: normal resting blood pressure (systolic: 80-160mmHg;
diastolic: 50-90mmHg), heart rate (50-90bpm), and ECG
5) Normal or corrected-normal vision
6) Cognitively Intact:

Shipley Institute of Living Scale (Zachary, 1991) verbal

intelligence score ≥ 80
Exclusion criteria:
1) Urinalysis:

positive for illicit substance use (opioids, methadone, cocaine

metabolites, benzodiazepines, barbiturates [≥300ng/ml], or amphetamines
[≥1000ng/ml]) or pregnancy (females only)
2) Recent substance use: 15+ days of marijuana and/or alcohol use in past month
3) Psychiatric evaluation: met criteria for current Axis I disorder (MINI-6)
4) Medical contraindications: diabetes, steroid-based contraceptives
5) MRI contraindications: pacemaker, ferrous implants, metal fragments
6) Current motivation to reduce, or seek treatment for, their nicotine use
7) Lactose intolerance (placebo dose)
Individuals (N = 27) who satisfied inclusion and exclusion criteria were deemed
eligible and invited to participate in the research study. Participants provided written
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informed consent to all experimental study procedures prior to the first experimental
session. Participants were scheduled for experimental sessions on non-consecutive
weekdays (M-F). Whenever possible, experimental sessions were scheduled within the
same week. Eligible female participants were scheduled for both experimental sessions
during their luteal phase (self-reported final 14 days of the menstrual cycle) to minimize
stress reactivity variability (Clemens Kirschbaum, Kudielka, Gaab, Schommer, &
Hellhammer, 1999; Kumsta, Entringer, Hellhammer, & Wüst, 2007). Participants who
completed both experimental sessions (N = 21) were included in outcome analyses.
3.2.3 Power Analyses
Power analyses for this study were based on the effect sizes observed in a related
study using similar experimental procedures. Prior research in our laboratory
(Greenwald et al., in preparation) demonstrated that similar pharmacological doses,
YOH 54mg + [HYD 0mg vs. 20mg], were associated with moderate effects on opioid
drug-seeking behavior (Cohen’s d = 0.62 and 0.68, respectively) in opioid-dependent,
buprenorphine-maintained volunteers. The pharmacological doses (YOH 54mg + HYD
10mg) used in the present study were assumed to be associated with similar effect
sizes (Cohen’s d = 0.64) on the primary outcome variable: nicotine-seeking and selfadministration behavior (see Choice Task section below). G*Power version 3.1
(Dusseldorf, Germany) indicated that a sample of 21 subjects would afford sufficient
statistical power to reliably detect a main effect for a two-tailed paired t-test, power =
.80, and α < .05 (J. Cohen, 1992).
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3.2.4 Experimental Procedures
Participants completed two experimental sessions (active vs. placebo stress;
random order) using a double-blind, placebo-controlled, and within-subject crossover
design. Participants were allowed to smoke cigarettes ad libitum prior to each
experimental session. Upon arrival at our laboratory (11:00am), participants were tested
for sobriety (expired breath alcohol < .002%). At 11:20am, a saliva sample was
collected, vital signs (resting blood pressure and heart rate) and expired breath CO (see
Physiological Measures section below) were measured, and the periodic battery of selfreport measures (see Periodic Self-Report Battery below) was completed (see Table
3.1 for complete experimental procedures). The periodic battery of self-report measures
was collected five times throughout each experimental visit and included: Minnesota
Nicotine Withdrawal Scale (MNWS), Brief Questionnaire of Smoking Urges (QSU),
State-Trait Anxiety Inventory (STAI; state version), and Positive and Negative Affect
Scale (PANAS). At 11:30am, participants completed the paced puff procedure.
Participants smoked one puff (1-2sec inhale; video-verified) of their preferred brand of
cigarette every minute for five minutes (6 total puffs; stopwatch timed; experimental
control of recent nicotine exposure; experimental room ventilated). At 11:40am,
participants were moved to a new experimental room that was not used for cigarette
smoking and was devoid of smoking/cigarette cues. A saliva sample was collected, and
vital signs and expired breath CO were measured. At 11:45am, participants selfadministered the oral YOH dose (54mg or 0mg). Prior research in our laboratory
(Greenwald et al., in preparation) indicated that an oral 54mg YOH dose elevated
resting blood pressure (relative to placebo; consistent with a physiological stress
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response) approximately 75min after dose and remained elevated for 2+ hours. For this
study, YOH was self-administered 75min prior to the onset of the MRI scan.
Participants completed another repetition of the self-report measure battery, as well as
the Timeline Follow-Back Questionnaire. At 12:15pm, participants self-administered the
oral HYD dose (10mg or 0mg). Prior research in our laboratory (Greenwald et al., in
preparation) demonstrated that oral HYD dose elevated saliva cortisol levels (relative to
placebo; consistent with a physiological stress response) approximately 45min after
dose and remained elevated for 2+ hours. Participants received detailed instructions
about the MRI scan procedure and experimental tasks, and completed practice runs of
the letter 2-back (until proficient). At 12:40am, periodic self-report questionnaires were
completed, vital signs were measured, and a saliva sample collected. Participants were
escorted to the MRI center (~8min walk) and upon arrival allowed to rest briefly (~34min),
MRI

while
room

the
was

prepared.
Participants
completed the MRI
safety screen with
the

MR

technologist (Dalal
Khatib) prior to the
scan (1-2pm; see
Neuroimaging

Table 3.1: Experimental Timeline. Experimental timeline was
identical for both experimental sessions (active and placebo stress).
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Experimental Tasks and Neuroimaging Parameters sections below). After being
escorted back to the Tolan Park Medical building (~8min walk) and following a brief rest
(~5min), a saliva sample was collected, vital signs were measured, and periodic selfreport measures were completed (2:20pm). At 2:28pm, participants were provided
verbal instructions that described the cigarette puff vs. money choice progressive ratio
task. From 2:30-3pm, participants completed the 30min choice task (see Choice Task
section below). At 3:00pm, vital signs were measured, a saliva sample was collected,
and the periodic self-report battery was completed. At 3:05pm, participants were
escorted to the cigarette-smoking experimental room (ventilated) and self-administered
the cigarette puffs earned on the choice task. Participants were instructed to smoke
exactly the number of earned puffs (not more and not fewer; 1-2sec inhale; videoverified) at a comfortable pace of their choosing. Inter-puff interval (s) was measured
via video monitor unbeknownst to the participant. Participants remained on site until
4pm for monitoring. Participants were not able to smoke ad libitum until after 4pm. Each
experimental session lasted 5 hours. Participants were compensated $70 at the end of
each experimental session and a bonus of $40 for completing both sessions (total
compensation for study completion: $200). Any money earned during the choice task
was added to the participant’s study payment.
Participant safety. Participant safety was paramount. Previous research in our
laboratory using comparable and higher YOH and HYD oral dose combinations were
not associated with adverse events. However, personnel and safety procedures were
established prior to participant enrollment to ensure participant safety throughout the
study. Medical staff (licensed physicians and nurses), clinical psychologists, trained
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masters-level clinical students, and research staff were onsite throughout each
experimental session. Medications were onsite and available to counteract YOH and
HYD if necessary [e.g. clonidine and/or diazepam; (Charney et al., 1983; Charney,
Woods, Krystal, Nagy, & Heninger, 1992; Mattila, Seppala, & Mattila, 1988)].
3.2.5 Physiological Measures
Vital signs: Resting heart rate and systolic and diastolic blood pressure were
measured during the in-person screening visit (index of cardiovascular health) and
periodically throughout each experimental session (biomarker of physiological stress
response) via Welch-Allyn vital signs monitor. In addition, heart rate and blood pressure
were monitored to ensure participant cardiovascular safety throughout the study (safety
thresholds; resting heart rate ≤ 100 beats/min and blood pressure ≤ 160 / 100 mmHg
[systolic / diastolic]).
Saliva measures:

Saliva was collected via oral swab (SalivaBio Oral Swab;

Salimetrics®, State College, PA) which was placed under the participant's tongue for ~2
minutes. After saliva collection, swabs were returned to the individual storage tube. At
the end of each experimental session, samples were spun down via centrifuge (3386
RPMs) for 15 minutes and stored upright at -80ºC until analysis and quantification.
Saliva α-amylase is a digestive enzyme and indirect biomarker of sympathetic ANS
activity (Nater & Rohleder, 2009). Saliva α-amylase responds to β-adrenergic receptor
stimulation, but prior research indicated α-amylase reflected indirect stimulation by YOH
(Ehlert et al., 2006). Saliva α-amylase was quantified (units: U/mL) via enzymatic
reaction with 2-chloro-p-nitrophenol and the change in spectrophotometric absorption at
405nm (sensitivity threshold: 0.4 U/mL). Salivary cortisol is a well-validated correlate of
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plasma cortisol levels and HPA axis activity (Kahn, Rubinow, Davis, Kling, & Post,
1988). HYD reliably and dose-dependently increases cortisol levels (van Stegeren,
Roozendaal, Kindt, Wolf, & Joëls, 2010). Saliva cortisol was quantified (units: ug/dL) via
ELISA assay and reaction with horseradish peroxidase enzyme, followed by
measurement of optical density at 450nm (sensitivity threshold: <0.007 ug/dL).
3.2.6 Self-Report Measures
The following self-report measures were administered during the in-person
screening visit only (unless otherwise noted). Drug History and Use Questionnaire: The
DHUQ was developed in-house as a comprehensive assessment of substance use
history (across drugs of abuse), including age at onset, use frequency, and substance
use consequences. This measure was used to determine participant eligibility (e.g.
past-month

cigarette

smoking

and

alcohol

use

frequency).

Medical

History

Questionnaire: The MHQ was developed in-house as a comprehensive self-report
assessment of participant medical history, including lifetime and current medical
diagnoses, reproductive status, current medication and contraceptive use. This
measure was used to determine participant eligibility (e.g. cardiovascular conditions,
medication allergies). Distress Tolerance Scale: This 15-item 5-point Likert scale (1 =
‘strongly agree’ to 5 = ‘strongly disagree’) measured an individual’s ability to tolerate
distress. This scale demonstrated good construct validity and reliability (Simons &
Gaher, 2005). Barratt Impulsivity Scale (BIS-11): This widely-used 30-item 4-point Likert
scale (0 = ‘rarely/never’ to 4 = ‘almost always/always) measured trait impulsivity (e.g. ‘I
plan tasks carefully’) along three dimensions: motor, attention, and non-planning
impulsiveness (Patton & Stanford, 1995; Stanford et al., 2009). State-Trait Anxiety
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Inventory (STAI; trait): The 20-item 4-point Likert scale (1 = ‘not at all’ to 4 = ‘very much
so’) measured trait anxiety (‘how you generally feel’) via first-person statements (e.g. ‘I
feel secure’) (Spielberger, 1983). The STAI has excellent psychometric properties
(Spielberger, 1983, 2010). Stress Mindset Scale (SMS): This 8-item 5-point Likert scale
(1 = ‘strongly disagree’ to 5 = ‘strongly agree’) measured an individual’s subjective
assessment (or experience) of how stress affected his/her performance, health, and
learning ability (e.g. ‘the effects of stress are negative and should be avoided’) (Crum,
Salovey, & Achor, 2013). Fagerstrom Test for Nicotine Dependence (FTND): The FTND
is the gold standard self-report questionnaire for assessing nicotine dependence. The
FTND consists of 6 items (e.g. ‘do you smoke more frequently in the morning?’ [yes=1,
no=0]) that are summed for a total score (range: 0-10) of nicotine dependence severity
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). Timeline Follow-Back
Questionnaire (TLFB): Participants completed the TLFB questionnaire once during
each experimental session. The TLFB assessed frequency of past week (7 days)
nicotine use across products (cigarettes, e-cigarettes, cigars, and smokeless tobacco).
3.2.7 Periodic Self-Report Battery
Questionnaires described below were administered periodically throughout each
experimental session (see Table 3.1). State-Trait Anxiety Inventory (STAI): The 20-item
4-point Likert scale (1 = ‘not at all’ to 4 = ‘very much so’) measured state anxiety (‘right
now, at this moment’) via first-person statements (e.g. ‘I feel calm’) (Spielberger, 1983).
Positive and Negative Affect Schedule (PANAS): The PANAS is a 20-item 5-point Likert
scale (1 = ’not at all or very slightly’ to 5 = ’extremely’) that is a reliable and wellvalidated measure of state positive and negative affect (Watson, Clark, & Tellegen,

42

1988). Participants rated 20 adjectives (e.g. ‘interested’ or ‘excited’) ‘at the present
moment.’ Items loaded onto one of two affect subscales: ‘positive’ or ‘negative’
(analyzed separately). Questionnaire of Smoking Urges (QSU; brief version): This 10item 7-point Likert scale (1 = ‘strongly disagree’ to 7 = ‘strongly agree’) measured a
participant’s desire to smoke a cigarette (e.g. ‘I have a desire for a cigarette right now’)
‘at this moment’ (Cox, Tiffany, & Christen, 2001). Items loaded onto one of two craving
subscales: ‘appetitive’ or ‘relief-motivated’ (analyzed separately). Minnesota Nicotine
Withdrawal Scale (MNWS): The MNWS consisted of 15 adjectives (descriptions of
possible nicotine withdrawal symptoms; e.g. ‘restless’ and ‘impatient’) rated on a 5-point
Likert scale (0 = ‘none’ to 4 = ‘severe’) (Hughes & Hatsukami, 1986). The MNWS is a
well-validated measure of nicotine withdrawal severity (Hughes, 1992; Hughes, Gust,
Skoog, Keenan, & Fenwick, 1991; Hughes & Hatsukami, 1986; Shiffman, West, &
Gilbert, 2004).
3.2.8 Neuroimaging Experimental Tasks
Participant scans were completed in the afternoon (1-2pm) for both experimental
sessions. Prior to each scan, participants completed an MRI safety assessment (~3min)
with the MR technologist (Dalal Khatib). All imaging was conducted on a 3 Tesla
Siemens Verio system with 32-channel receive-only head coil. Experimental tasks were
programmed using Presentation software version 18.1 and displayed on-screen inside
the MRI scanner via projection system. Participants were able to communicate with the
MR technologist via speaker/microphone system.
1

H fMRS Letter 2-back Task. The letter 2-back task paradigm (Figure 3.4) was a

shortened version of the letter 2-back task paradigm used in the pilot study. The pilot
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Figure 3.4: 1H fMRS Dissertation Study Experimental Paradigm. The letter 2-back task
(right) consisted of two phases: flashing checkerboard (3Hz, 208s) and five repetitions of
letter 2-back (64s; instructions ‘2-back’ [4s], 20 letters [3s/letter; 60s]) with interleaved
fixation cross rest (instructions ‘Rest’ [2s] and static fixation cross rest [30s]).

study contained seven blocks of alternating letter 2-back and interleaved fixation-cross
rest, while this version contained only five blocks. All other aspects of the task paradigm
and instructions were identical. Briefly, the task consisted of two phases: flashing
grayscale checkerboard (3Hz; 208s) and 5 blocks of alternating letter 2-back (64s; onscreen ‘2-back’ instructions [4s] followed by 20 capitalized letters [3s/letter; 6 target
letters; each letter [500ms] followed by blank screen [2500ms]) and interleaved fixationcross rest (32s; ‘Rest’ instructions [2s], static fixation-cross [30s]). Participants indicated
(via button press) if the letter on screen matched the letter presented two previously.
Participants were not provided feedback about response accuracy. Response accuracy
was quantified as a percentage of correct responses for each task block.
fMRI Letter 2-back Task. The fMRI version of the letter 2-back task consisted of
two blocks of letter 2-back (64s; same parameters as 1H fMRS version) and fixation-
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Figure 3.5: fMRI Smoking Cued N-back Paradigm. Participants completed two blocks of
each task difficulty (0-, 1-, and 2-back) of letter N-back yoked with neutral or smokingrelated images. Each block (32s) consisted of instructions (e.g. ‘1-Back’; 2s) and 10
letters (3s/letter) interleaved with fixation cross (16s).

cross rest (32s). The fMRI letter 2-back task blocks were mixed in among blocks of the
smoking vs. neutral cued N-back task.
fMRI Smoking vs. Neutral Cued N-back Task. This task consisted of blocks of
letter 0-, 1-, and 2-back overlaid in the center of either cigarette smoking-related images
or neutral, non-smoking images (Figure 3.5; matched for image characteristics and
content [e.g. image of a hand with and without a lit cigarette]). Two blocks of each Nback category (e.g. 0-back smoking cued, 1-back neutral cued, etc.) was displayed in
pseudo-random order. Each block had an identical structure (32s; instructions [e.g. ‘1back’; 2s], 10 letters [3s/letter; 750ms on-screen, 2250ms blank screen; 3 targets])
separated by fixation-cross rest (16s; not analyzed; minimize carry-over effects).
Participants were instructed to focus on the letters in the center of screen (as they
would during a letter N-back task) and indicate (via button press) when the current letter
on screen matched the target letter (0-back), when the same letter was depicted
sequentially (1-back), or when the current letter matched the letter presented two
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previous (2-back). Participant performance (% correct and response latency [ms]) was
analyzed separately for each N-back trial (0-, 1-, and 2-back) and image type (smoking
vs. neutral).
Cerebrovascular Reactivity (CVR) Task.

Following the fMRI N-back task, a

subset of participants completed the CVR task. The task consisted of five blocks of
unconstrained ‘normal’ breathing (22s), paced breathing (4 repetitions of breathing in
[3s] and out [3s]), and breath-hold challenges (11s; following exhale). On-screen
instructions guided participant breathing throughout the task (Figure 3.6). Prior research
demonstrated that breath-hold challenge tasks were robust and reliable measures of
CVR (Bright & Murphy, 2013; Lipp, Murphy, Caseras, & Wise, 2015; Magon et al.,
2009; Murphy, Harris, & Wise, 2011; Sousa, Vilela, & Figueiredo, 2014). Carbon
dioxide is a powerful vasodilator. As carbon dioxide accumulates in blood vessels
during breath hold, cerebral blood flow will increase substantially. The ratio of

Figure 3.6: Cerebrovascular Reactivity Paradigm. Participants were instructed to alter
their breathing to match the instructions on screen. Three phases were completed
sequentially across five repetitions: normal (uncontrolled; 22s), paced breathing (3s in/
3s out; four repetitions), and breath hold (11s).
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oxygenated hemoglobin to deoxygenated hemoglobin will increase which will alter local
T2* decay, resulting in a robust BOLD signal (relative to periods of paced breathing).
The source of the CVR BOLD signal is vascular (i.e. non-neuronal). Thus, this task
facilitated identification of clusters throughout the brain that differed as a function of
active vs. placebo stress. Clusters identified on this task were subtracted from betweensession contrasts of interest (see Analysis Strategy section below for a detailed
explanation).
3.2.9 Neuroimaging Parameters
All imaging was conducted on a 3 Tesla Siemens Verio system with 32-channel
receive-only head coil. High-resolution T1-weighted structural scans were collected
using the 3D MPRAGE sequence with the following parameters: TR = 2.2s, TE = 3ms,
TI = 799ms, flip angle = 13°, FOV = 256x256x160mm, 256 x 1mm thick axial slices,
matrix = 176 x 256. Prior to 1H fMRS acquisition, a region of the left dlPFC (2.5 x 2.5 x
2.5cm) larger than 1H fMRS voxel was shimmed to improve B0-field homogeneity
(FASTESTMAP). 1H fMRS spectra were continuously acquired every 16s (PRESS with
OVS and VAPOR, TE = 23ms, TR = 4.0s, 4 averages/spectrum, bandwidth = 2 kHz,
2048 data points, no apodization) during the letter 2-back task (42 spectra, 672s). 1H
fMRS spectra were acquired without water suppression immediately after the task (TE =
23ms, TR = 10s, 2 averages/spectrum, bandwidth = 2 kHz, 2048 data points, no
apodization). Unsuppressed water levels were used to scale metabolite levels to
absolute concentration values during each task (mmol/kg wet weight). BOLD fMRI data
were collected continuously throughout the N-back and CVR tasks using a gradient
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echo planar imaging sequence with the following acquisition parameters: TE = 36ms,
TR = 2.83s, matrix = 80x80, 40 interleaved slices, voxel size = 2.9mm isotropic.
3.2.10 Choice Task
The choice progressive ratio task was the only opportunity for participants to
smoke cigarette puffs (after the 11:30am paced puff procedure) during either
experimental session (until after the 4pm discharge). During this task, participants were
seated at a computer and could earn (via computer ‘mouse’ clicking) one puff of their
preferred brand of cigarette or a money alternative ($0.25 [amount based on prior
study] (Tidey, Higgins, Bickel, & Steingard, 1999)) on 11 independent choice trials. On
each trial, the participant was able to earn a cigarette puff, money, or do nothing (not
punished). Once an option (cigarette puff vs. money) was selected on each trial, the
participant had to satisfy each trial’s response requirement (escalating number of
mouse clicks for each subsequent trial [progressive ratio schedule]; i.e., 5, 12, 33, 100,
180, 340, 540, 835, 1220, 1660 and 2275 clicks) to earn that unit of the option selected.
Participants could earn any combination of cigarette puffs or money that summed to a
total of 11 units. After the 30min task, participants were presented with the earned units
(money was added to their study payment). Participants were instructed to smoke the
exact number of puffs earned (not more or less) at the pace of their choosing.
Participants were instructed to inhale 1-2s for each cigarette puff and were videomonitored to verify compliance. Number of puffs earned and smoked during each
experimental session is a direct measure of appetitive nicotine motivation and will be
referred to as ‘nicotine-seeking and self-administration’ hereafter. Unbeknownst the
participant, the amount of time between cigarette puffs was timed via stopwatch and
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mean inter-puff interval (s) was calculated for each experimental session. Inter-puff
interval was a direct measure of nicotine consumption rate. Nicotine-seeking and selfadministration (appetitive phase) was analyzed separately from nicotine consumption
rate (consumptive phase).
3.2.11 Analysis Strategy
1

H fMRS Analyses.

1

H fMRS spectra were analyzed using LCModel version 6.3

(Provencher, 2008). Post-processing and metabolite quantification steps were 100%
automated. Eddy current effects were corrected using the unsuppressed water signal
(Klose, 1990). T1-weighted structural images were B1 field corrected, the brain image
extracted, and segmented into partial volume maps of CSF, grey and white matter
using FreeSurfer and FSL tools (e.g. FLIRT, BET, and FAST) (Dale et al., 1999; Smith
et al., 2004). Finally, tissue composition within the MRS voxel and appropriate
correction factors (e.g. T1 and T2 relaxation) were used to calculate the absolute
glutamate (GLU) concentration (mmol/kg wet weight) (J. A. Stanley et al., 1995). Two
outcome analysis strategies were employed in this study. First, raw spectra were
phase- and shift-corrected. Consecutive raw spectra (4 averages, 16s, no apodization
or zero-filling) were averaged which resulted in 32s (8 averages) temporal resolution.
LCModel fit characteristics demonstrated that this temporal resolution was at the lower
limit of reliable GLU quantification. Therefore, a second analysis strategy was used: 64s
temporal resolution moving average. 32s resolution spectra from the first approach
were averaged across consecutive task blocks (moving average: 64s resolution) to
improve signal-to-noise (SNR) and fit reliability. Therefore, spectra collected during first
32s of letter 2-back task block 1 (2-back A) were averaged with spectra collected during
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first 32s of letter 2-back task block 2 (2-back A; and so on for 2-back B and rest). Mean
metabolite levels during 2-back task were contrasted with interleaved fixation-cross rest.
The metabolite of interest for this study was GLU. However, other metabolites (NAA,
Myo-Inositol, GPC+PC, and PCr+Cr) were also analyzed to determine the
neurochemical specificity of working memory task modulation.
1

H fMRS voxel overlap was quantified using the avp_overlap script (Woodcock et

al., 2017). 3D Geometric voxel overlap percentage was calculated between each
subject’s voxel and the template voxel (i.e. accuracy), and across all subjects (i.e.
reliability).
fMRI Analyses. Statistical Parametric Mapping (SPM) version 8 software was
used to process the raw fMRI data. Raw data were slice time-corrected, motioncorrected, high-pass filtered (128Hz), coregistered to the Montreal Neurologic Institute
(MNI) template space, spatially-smoothed (6mm Gaussian kernel), and resliced (2mm
isotropic) prior to outcome analyses. First-level contrast maps (e.g. 1-back smoking
cued > 1-back neutral cued; within-subject) were submitted to group-level, randomeffects analyses (FTND included as a covariate) and cluster-level corrected (AFNI
3dClustSim; p < .05). FTND was included as a covariate for three reasons: 1) chronic
cigarette smoking has known vascular effects and thus could alter the BOLD signal, 2)
chronic cigarette smoking could alter smoking cue salience and thus BOLD response,
and 3) to be consistent with the analysis strategy used for other variables. Regions of
interest included:

ventrolateral [vl] PFC (Brodmann areas 44 and 45), dlPFC

(Brodmann Area 46), dPFC (Brodmann area 9), dorsal anterior cingulate (dACC),
mOFC, mPFC, striatum, insula and amygdala. Within an experimental session, clusters
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that survived cluster-level correction were considered significant and interpreted. For
comparisons between experimental sessions (active vs. placebo stress), an additional
analysis step was implemented. First-level CVR contrast maps (breath hold > paced
breathing) were submitted to group-level, random-effects analyses. Between-session
CVR contrasts (active > placebo stress and placebo > active stress) were saved as
thresholded maps (voxel-level; p < .05). Using ImCalc in SPM8, CVR between-session
difference maps were subtracted from cluster-level corrected between-session
contrasts of interest (e.g. active > placebo stress: 1-back smoking image > 1-back
neutral image) to remove regions that exhibited vascular reactivity differences as a
function of active vs. placebo stress. This approach reduced the likelihood of false
positive clusters (i.e. removed clusters attributed to vascular effects [non-neuronal] of
the stress manipulation) for between-session contrasts of interest.
1

H fMRS vs. fMRI comparison. Parameters for the 1H fMRS and fMRI letter 2-

back tasks were identical which enabled an exploratory comparison of 1H fMRS GLU
levels and fMRI BOLD response. First, each subject’s 1H fMRS voxel was recreated in
subject space then coregistered to the SPM template brain. Next, the 1H fMRS voxel
was used as a mask for first-level BOLD contrasts (letter 2-back > fix cross rest) at the
same temporal resolution as 1H fMRS (32s; 2-back A and B). Z scores (peak activation)
and peak cluster extents were extracted for each subject and correlated with GLU
levels during letter 2-back task performance. fMRI metrics (Z score and cluster extents)
were compared with 1H fMRS GLU levels for 2-back A and B for each task repetition
(first 1H fMRS task block was excluded; practice effects) using bivariate Pearson
correlations. The analysis space consisted of a correlation matrix with 32 cells (4 fMRI
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2-back blocks X 8 1H fMRS 2-back blocks) for both Z scores and cluster extents for
each of the placebo and stress sessions. For this exploratory analysis only, the
statistical threshold was p ≤ .10.
All self-report, behavioral, physiological and neurochemical data were evaluated
for missing data, extreme values, and normality (Shapiro-Wilk test of normality;
skewness and kurtosis statistics > 1.5) (West, Finch, & Curran, 1995). Ordinal and
continuous variable distributions were normalized with statistical transformations (log10)
or winsorization (extreme values) prior to outcome analyses. Ordinal or continuous
variables measured at only one time point were evaluated using one-way ANOVA,
Pearson bivariate correlations, or linear regression. Ordinal or continuous variables
collected repeatedly across multiple time points (e.g. physiological, periodic self-report,
N-back behavioral data, and neurochemistry) were evaluated using rmANOVA. Followup paired t-tests evaluated differences for any significant rmANOVA main effects.
Sphericity was verified (Mauchly’s test of sphericity) prior to rmANOVA analyses.
Categorical variables were evaluated using Chi-Square test of independence. FTND
score was evaluated as a covariate for all outcome variables (only included in analytic
models when significant). Descriptive statistics are presented as mean ± one standard
deviation (M ± 1 SD) unless otherwise noted. In figures, error bars represent ± one
standard error of the mean (SEM) unless otherwise noted. The threshold for statistical
significance was p ≤ .05.
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CHAPTER 4 RESULTS
4.1 1H fMRS Pilot Study
4.1.1 Sample Characteristics
The modal participant was a 24 year old (± 3.4 yrs; range: 19-30 yrs) Caucasian
or Asian (50% each) male (56.3%). The sample consisted of cognitively-normal and
psychiatrically-healthy college-educated participants not currently taking psychoactive
medications. All participants were right hand dominant.
4.1.2 Voxel Overlap

Figure 4.1: 1H fMRS Pilot Study Voxel Overlap. Participant voxel placement (N=16) was
coregistered to template space and orthonormal views depict geometric voxel overlap.
Percentage of geometric voxel overlap is indicated by color: white indicates voxel space
with complete overlap, yellow/red indicate incomplete overlap, across all subjects.

AVP was used to prescribe each participant’s voxel location (less one subject
due to experimenter error; manual placement). Voxel placement was highly accurate
(mean percent geometric overlap with the template voxel = 92.3 ± 4.7%) and reliable
(mean percent geometric overlap across all participants = 89.9%) across all participants
(Figure 4.1) (Woodcock et al., 2017). Mean (± one SD) voxel tissue composition was
36.8 ± 3.8% gray and 60.8 ± 4.5% white matter. Voxel placement was less accurate for
the one subject without AVP (manual placement: 77.7% vs. AVP: 86.2-96.9%).
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4.1.3 Behavioral Data
Behavioral

data

demonstrated

task

compliance

(mean

correct: 94.8% ± 10.7%;
mean reaction time: 644 ±
171ms).

rmANOVA

indicated

that

performance
across

task

increased

blocks

(Time

effect; F(6,90) = 2.39, p <
.05, from 88.5% in block

Figure 4.2: Letter 2-back Response Accuracy. Mean
response accuracy (% correct) is depicted across task
blocks (± 1 SEM).

1 to 96.9% in block 7;
Figure 4.2). Reaction time
non-significantly
decreased across blocks
(F(6,90) = 1.90, p = .09,
from 697ms in block 1 to
638ms in block 7; Figure
4.3).

Figure 4.3: Letter 2-back Response Latency. Mean response
latency (s) is depicted across task blocks (± 1 SEM).
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1

Figure 4.4: LCModel Fit of Representative Spectrum. A representative quality H fMRS
spectrum (32s temporal resolution; 8 avgs) is depicted. The raw (black line) and
LCModel fit (red line) signal are displayed above the estimated spectral peaks for GLU
(red line). At the bottom of the figure, the residual signal (black line; i.e. noise) and
chemical shift (ppm) are displayed.

4.1.4 LCModel Fit Characteristics
LCModel fit reliability was evaluated for continuous fixation-cross rest, letter 2back A (first 32s of each task block), letter 2-back B (final 32s of each task block), and
interleaved fixation-cross rests (between 2-back task blocks). Importantly, LCModel fit
characteristics did not differ as a function of 2-back vs. rest (Time and Task X Time
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Table 4.1: LCModel Fit Characteristics. Mean (± 1 SD) LCModel fit characteristics
are presented by task phase. GLU = glutamate; GLN = glutamine; FWHM = fullwidth half-maximum; SNR = signal-to-noise; CRLB = Cramer Rao Lower Bound.

effects examined; ps > .10; see Table 4.1). A representative spectrum and LCModel
estimation of GLU levels are depicted in Figure 4.4.
4.1.5 GLU Modulation
Flashing checkerboard reduced GLU level fluctuation (mean coefficient of
variation percentage = 4.6%) prior to 2-back (vs. rest) modulation.
2-back A vs. rest. GLU levels during 2-back A (first 32s of task performance
across task blocks) were compared to continuous and interleaved fixation-cross rest
(Figure 4.5). Overall, GLU
levels
were
(3.4%)

during

2-back

A

significantly higher
than

continuous

fixation-cross

rest

3.4% higher*
2.9% higher (p = .07)

(F(1,111) = 6.26, p < .05,
2

partial η = 0.05 [small-tomoderate

effect

size];

12.07 ± 0.85 vs. 11.75 ±
1.00, respectively). Overall
2-back A GLU levels did

Figure 4.5: Overall GLU Levels. Mean (± 1 SEM) GLU levels
for each task phase are depicted. Paired t-test: *p < .05
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not

differ

interleaved

from
fixation-

cross rest (p = .92;
12.07 ± 0.85 vs. 12.06
± 1.04, respectively).
Relative
continuous

to
fixation-

cross rest, rmANOVA
indicated a significant
Time effect (F(6,90) =
3.35, p < .01, partial η2
= 0.18 [moderate-tolarge effect size]) as
GLU levels increased
across

task

blocks

(Figure 4.6). Task (2back A vs. rest) and
Time

X

interaction
were

Task
effects

non-significant

(ps > .20).
Relative
interleaved

to
fixation-

Figure 4.6 & 4.7: GLU Levels across Task Blocks. Mean (± 1
SEM) 2-back GLU levels vs. continuous fixation-cross (upper
panel) and interleaved fixation-cross (lower panel) are
depicted across task blocks.
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cross

rest,

rmANOVA

indicated significant Time

*

(F(6,90) = 2.78, p < .05,
η2

partial

=

0.16

[moderate-to-large effect
size]) and Time X Task
interaction

effects

(F(6,90) = 2.95, p < .05,
η2

partial

=

0.16

[moderate-to-large effect
size]; Figure 4.7). The
Task

effect

was

not

significant (p = .52). The
Time effect indicated that
GLU

levels

increased

across task blocks. The
Time X Task interaction
confirmed

that

GLU

levels were significantly
higher

(4.4%)

interleaved
task

blocks

rest
2

than
during
and

3

(F(1,31) = 8.49, p < .01,

Figure 4.8 & 4.9: 2-back A & B GLU Levels vs. Continuous
Fixation Cross. Mean (± 1 SEM) 2-back A (upper panel) and
B (lower panel) GLU levels (% relative to continuous fixation
cross) are depicted across task blocks. Paired t-test: *p <
.05, **p < .01
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partial

η2

=

0.22

[moderate-to-large effect
size]; 11.98 ± 0.71 vs.
11.48

±

*

1.01,

respectively; Figure 4.10),
and

significantly

lower

(4.8%) during task blocks
4 and 5 (F(1,31) = 12.39,
p < .001, partial η2 = 0.29

*

[large effect size]; 11.91 ±
0.97 vs. 12.49 ± 0.94,
respectively).

*

2-back B vs. rest.
Overall GLU levels during
2-back B (final 32s of
task performance across
task blocks) were nonsignificantly higher (2.9%)
**

than continuous fixationcross rest (F(1,111) =
3.28, p = .07, partial η2 =
0.03

[small-to-moderate

effect size]; 12.00 ± 0.98

Figure 4.10 & 4.11: 2-back A & B GLU Levels vs.
Interleaved Fixation Cross. Mean (± 1 SEM) 2-back A (upper
panel) and B (lower panel) GLU levels (% relative to
interleaved fixation cross) are depicted across task blocks.
Paired t-test: *p < .05, **p < .01
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vs. 11.75 ± 1.00, respectively; Figure 4.5). Overall GLU levels during 2-back B did not
differ from interleaved fixation-cross rest (p = .61; 12.00 ± 0.98 vs. 12.06 ± 1.04,
respectively).
Relative to continuous fixation-cross rest, rmANOVA indicated a non-significant
Time effect (F(6,165) = 2.08, p = .06; partial η2 = 0.12 [moderate-to-large effect size]) as
GLU levels increased across task blocks (Figure 4.6). Task (2-back B vs. rest) and
Time X Task interaction effects were non-significant (ps > .20).
Relative to interleaved fixation-cross rest, rmANOVA indicated significant Time
(F(6,90) = 3.14, p < .01, partial η2 = 0.17 [moderate-to-large effect size]) and Time X
Task interaction effects (F(6,90) = 3.71, p < .01, partial η2 = 0.20 [moderate-to-large
effect size]; Figure 4.10). The Task effect was not significant (p = .91). The Time effect
indicated that GLU levels increased across task blocks (Figure 4.7). The Time X Task
interaction indicated that GLU levels were significantly higher (4.4%) than interleaved
rest during task blocks 2 and 3 (F(1,31) = 7.28, p < .05, partial η2 = 0.19 [moderate-tolarge effect size]; 11.98 ± 0.93 vs. 11.48 ± 1.01, respectively; Figure 4.11), and
significantly lower (3.6%) during task blocks 4, 5, and 6 (F(1,47) = 8.74, p < .01, partial
η2 = 0.16 [moderate-to-large effect size]; 12.00 ± 0.93 vs. 12.44 ± 1.00, respectively).
4.1.6 BOLD Effect
Prior 1H fMRS studies found a significant BOLD effect as a function of task vs.
rest (Mangia et al., 2006; Schaller et al., 2013; Schaller et al., 2014). Increased
concentration of oxygenated blood in task-active brain regions (i.e. BOLD effect) can
reduce spectral linewidth (FWHM). Relative to continuous fixation-cross rest, rmANOVA
revealed FWHM did not significantly differ as a function of 2-back A or B (Task ps > .80;
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Time X Task interaction ps > .07). Relative to interleaved fixation-cross rest, rmANOVA
indicated that FWHM did not significantly differ as a function of 2-back A or B (Task ps
> .10; Time X Task interaction ps > .40).
4.1.7 Neurochemical Specificity
Metabolites other than GLU (Myo-Inositol, GPC+PC, PCr+Cr, and NAA) were
examined as a function of experimental task. During 2-back A, no metabolites (other
than GLU) differed as a function of task. However, during 2-back B, rmANOVA
indicated Time X Task interaction effects for Myo-Inositol and NAA (F(6,90) = 2.57, p <
.05 and F(6,90) = 2.28, p < .05, respectively). Myo-Inositol and NAA levels were higher
during 2-back B than interleaved fixation-cross rest in the first few task blocks, but
converged in later task blocks. GPC+PC and PCr+Cr did not differ significantly as a
function of task during 2-back A or B (ps > .05).
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4.2 Dissertation Study
4.2.1 Sample Characteristics
The modal participant was 28 (±
3.9) years old (range: 21-34 years),
male (85.7%), and African-American
(71.4%). Participants (N = 21) reported
smoking 17.2 ± 5.9 cigarettes/day and
were moderately nicotine dependent
(FTND

=

6.1

±

2.0).

Sample

characteristics are described in detail in

Table
4.2:
Characteristics.

Dissertation

Sample

Table 4.2.
4.2.2 Physiological Effects
Physiological and periodic selfreport measurements from the first

**

**

time point of each session (11:20am;
prior

to

exposure

experimental
control

procedure])

were

nicotine

[paced

puff

excluded

from

analyses for the following reasons.
Participant data were highly variable
at

the

initial

time

point,

which

suggested external factors influenced
participant physiology and self-report

Figure 4.12: Systolic Blood Pressure. Mean (±
1 SEM) systolic blood pressure (mmHg) is
depicted for active (green line) and placebo
stress sessions (blue line). Approximate
experimental procedure timing is noted with
arrows. Paired t-test: *p ≤ .05; **p < .01
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responses. Moreover, several participants reported they did not have access to
cigarettes in the morning before the start of the experimental session (and were in mild
nicotine withdrawal). Acclimation to the experimental setting and experimental control
for recent nicotine exposure established a more stable baseline measurement.
Therefore, only the final four time points for physiological indices and the periodic selfreport battery were included in outcome analyses.
Blood pressure. As a function of time point and experimental condition (active
vs. placebo stress), rmANOVA indicated that systolic BP (mmHg) exhibited significant
Time (F(3,57) = 4.14, p < .01; partial η2 = 0.18 [moderate-to-large effect size]), Dose
(F(1,19) = 10.31, p < .01; partial η2 = 0.35 [large effect size]), and Time X Dose
interaction effects (F(3,57) = 8.33, p <
.001; partial η2 = 0.31 [large effect
size];

Figure

4.12).

YOH+HYD

significantly increased systolic BP for

**
*

2+ hours throughout the remainder of
the

stress

session.

At

peak

YOH+HYD effects, systolic BP was
~11.5 mmHg higher during active vs.
placebo stress (128.8 mmHg vs.
117.5

mmHg).

FTND

was

not

significantly related to systolic BP (ps
> .20).

Figure 4.13: Diastolic Blood Pressure. Mean
(± 1 SEM) diastolic blood pressure (mmHg) is
depicted for the active stress (green line) and
placebo sessions (blue line). The approximate
timing of each experimental procedure is noted
with arrows. Paired t-test: *p ≤ .05; **p < .01

63

rmANOVA indicated that diastolic BP (mmHg) exhibited significant Time (F(3,57)
= 5.88, p < .001; partial η2 = 0.24 [large effect size]), Dose (F(1,19) = 6.65, p < .05;
partial η2 = 0.26 [large effect size]), and Time X Dose interaction effects (F(3,57) = 2.98,
p < .05; partial η2 = 0.14 [moderate-to-large effect size]) as a function of time point and
experimental condition (Figure 4.13). YOH+HYD significantly increased diastolic BP for
2+ hours throughout the remainder of the stress session. At peak effects, diastolic BP
was ~7 mmHg higher during active vs. placebo stress (79.6 mmHg vs. 72.5 mmHg).
FTND was not significantly related to diastolic BP (ps > .25).
Heart rate. rmANOVA indicated that HR (bpm) exhibited non-significant Time
(F(3,57) = 2.58, p = .06; partial η2 = 0.12 [moderate-to-large effect size]) and Dose
effects (p = .42), but there was a
significant Time X Dose interaction
(F(3,57) = 3.38, p < .05; partial η2 =
0.15 [moderate-to-large effect size];
Figure

4.14).

HR

decreased

significantly over time during the
placebo session (F(3,57) = 3.92, p <
.01; partial η2 = 0.09 [moderate effect
size]), but not the active stress
session (p = .55). At peak YOH+HYD
effects, HR was ~4 bpm faster during
active vs. placebo stress (77.8 bpm

Figure 4.14: Heart Rate. Mean (± 1 SEM)
heart rate (bpm) is depicted for the active
stress (green line) and placebo sessions (blue
line). The approximate timing of each
experimental procedure is noted with arrows.
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vs.

73.7

bpm).

FTND

was

not

significantly related to HR (ps > .35).
Saliva cortisol. Due to budget

**

restrictions, saliva biomarker data
(cortisol and α-amylase) were only
analyzed

at

three

time

points

(baseline, after YOH+HYD dosing but
**

prior to the MRI scan, and after the
puff/money choice task but prior to
earned nicotine self-administration).
rmANOVA
cortisol

indicated

(ug/dL;

that

saliva

log10-transformed)

exhibited significant Time (F(2,38) =
13.59, p < .001; partial η2 = 0.42 [very

Figure 4.15: Saliva Cortisol. Mean (± 1 SEM)
saliva cortisol (ug/dL) is depicted for the active
stress (green line) and placebo sessions (blue
line). The approximate timing of each
experimental procedure is noted with arrows.
Paired t-test: *p ≤ .05; **p < .01

large effect size]), Dose (F(1,19) = 29.14, p < .001; partial η2 = 0.61 [very large effect
size]), and Time X Dose interaction effects (F(2,38) = 25.13, p < .001; partial η2 = 0.57
[very large effect size]; Figure 4.15). YOH+HYD significantly increased saliva cortisol
levels for 2+ hours throughout the remainder of the stress session. At peak YOH+HYD
effects, saliva cortisol level was ~4x higher during active vs. placebo stress session.
FTND was not significantly related to saliva cortisol level (ps > .40).
Saliva α-amylase. rmANOVA indicated that saliva α-amylase (U/mL) exhibited a
significant Time effect (F(2,38) = 4.50, p < .05; partial η2 = 0.19 [moderate-to-large
effect size]), but non-significant Dose (p = .57) and Time X Dose interaction effects (p =
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.13; Figure 4.16). Saliva α-amylase
levels increased significantly over
time during the active stress session
(F(2,38) = 5.02, p < .05; partial η2 =
0.21 [moderate-to-large effect size]),
but not the placebo session (p = .25).
At peak YOH+HYD effects, saliva αamylase level was 28.7% higher
during

active

vs.

placebo

stress

session. FTND was not significantly
related to saliva α-amylase level (ps >
.20).
4.2.3
Magnitude
Manipulation
The

of

magnitude

Stress

of

Figure 4.16: Saliva α-Amylase. Mean (± 1
SEM) saliva α-amylase (U/ml) is depicted for
the active stress (green line) and placebo
sessions (blue line). The approximate timing of
each experimental procedure is noted with
arrows.

the

physiological stress response was an important experimental design consideration. If
the YOH and HYD doses induced physiological responses beyond a naturalistic level,
the generalizability of study findings might be limited. Thus, to provide context for the
magnitude of the physiological effects described above, the observed pharmacological
stress data were qualitatively compared with published studies that used psychosocial
stress manipulations.
With regard to saliva cortisol (biomarker of HPA axis response), a meta-analysis
of psychosocial stress manipulations and saliva cortisol response was examined
(Dickerson & Kemeny, 2004). A robust psychosocial stress manipulation (public
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speaking + cognitive tasks) used in 23 different studies conducted in the afternoon
(consistent with the present study; an important consideration because of the diurnal
rhythm of cortisol) was associated with a large effect on saliva cortisol (Cohen’s d =
1.09). Similarly, peak saliva cortisol response to YOH+HYD was also a large effect
(Cohen’s d = 1.61). With regard to cardiovascular biomarkers, a recent study of 102
cigarette smokers was selected for comparison (Ginty et al., 2014). A similar
psychosocial stress manipulation (public speaking + cognitive tasks) exhibited large
effects on systolic BP and HR (Cohen’s d = 1.18 and 1.53, respectively) (Ginty et al.,
2014). In the present study, YOH+HYD was associated with a comparable peak effect
on systolic BP (Cohen’s d = 1.17;
range = 0.96-1.37) and smaller
effect on HR (Cohen’s d = 0.26;
range = 0.19-0.32). Collectively,
these

qualitative

demonstrated
physiological

the

comparisons
magnitude

stress

of

response

induced by oral pretreatment with
54mg YOH and 10mg HYD was
comparable

to

a

robust

psychosocial stress manipulation.
4.2.4 Subjective Effects
Nicotine withdrawal. Nicotine
withdrawal

symptoms

were

Figure 4.17: Nicotine Withdrawal. Mean (± 1
SEM) self-reported nicotine withdrawal symptom
severity is depicted for the active stress (green
line) and placebo sessions (blue line). The
approximate timing of each experimental
procedure is noted with arrows.
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measured via self-report (MNWS)
as part of the periodic self-report
battery. rmANOVA indicated that
nicotine

withdrawal exhibited

a

significant Time effect (F(3,54) =
18.15, p < .001; partial η2 = 0.50
[very large effect size]), but nonsignificant Dose (p = .83) and Time
X Dose interaction effects (p = .67;
Figure 4.17). Nicotine withdrawal
symptoms increased significantly
throughout

each

experimental

session, but did not differ as a
function

of

active vs. placebo

stress. Mean nicotine withdrawal
severity was ‘slight’ or ‘mild’ at
peak

levels.

significantly

FTND
related

was
to

not

nicotine

withdrawal (ps > .06).
Appetitive cigarette craving.
Appetitive craving was measured
via self-report (QSU) as part of the
periodic

self-report

battery.

Figures 4.18 & 4.19: Appetitive and ReliefMotivated Cigarette Craving. Mean (± 1 SEM) selfreported appetitive (upper panel) and reliefmotivated (lower panel) cigarette craving is
depicted for the stress (green line) and placebo
sessions (blue line). The approximate timing of
each experimental procedure is noted with arrows.
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rmANOVA indicated that appetitive craving exhibited a significant Time effect (F(3,51) =
34.02, p < .001; partial η2 = 0.67 [very large effect size]), but non-significant Dose (p =
.62) and Time X Dose interaction effects (p = .12; Figure 4.18). Appetitive cigarette
craving increased significantly throughout each experimental session, but did not differ
as a function of active vs. placebo stress. At peak levels, appetitive cigarette craving
was ‘moderate’ to ‘substantial.’ FTND was not significantly related to appetitive craving
(ps > .20).
Relief-motivated cigarette craving.

Relief-motivated craving was measured via

self-report (QSU) as part of the periodic self-report battery. rmANOVA indicated that
relief-motivated craving (log10-transformed) exhibited a significant Time effect (F(3,51) =
25.31, p < .001; partial η2 = 0.60 [very large effect size]), but non-significant Dose (p =
.77) and Time X Dose interaction effects (p = .18; Figure 4.19). Relief-motivated
cigarette craving increased significantly throughout each experimental session, but did
not differ as a function of active vs. placebo stress. At peak levels, relief-motivated
cigarette craving was ‘moderate’ to ‘substantial.’ FTND was not significantly related to
relief-motivated craving (ps > .30).
Anxiety. Anxiety levels were measured via self-report (STAI; state version) as
part of the periodic self-report battery. rmANOVA indicated that anxiety exhibited a
significant Time effect (F(3,54) = 8.61, p < .001; partial η2 = 0.32 [large effect size]), but
non-significant Dose (p = .49) and Time X Dose interaction effects (p = .81; Figure
4.20). Anxiety levels decreased significantly throughout each experimental session, but
did not differ as a function of active vs. placebo stress. At peak levels (baseline),
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participants

reported

they

were

‘somewhat’ anxious. FTND was not
significantly related to anxiety (ps >
.15).
Negative

affect.

Negative

affect was measured via self-report
(PANAS) as part of the periodic selfreport battery. rmANOVA indicated
that

negative

affect

exhibited

a

significant Time effect (F(3,54) = 3.81,
p < .05; partial η2 = 0.18 [moderate-tolarge effect size]), but non-significant
Dose (p = .47) and Time X Dose

Figure 4.20: Anxiety. Mean (± 1 SEM) selfreported anxiety level is depicted for the active
stress (green line) and placebo sessions (blue
line). The approximate timing of each
experimental procedure is noted with arrows.

interaction effects (p = .34; Figure 4.21). Negative affect increased significantly
throughout each experimental session, but did not differ as a function of active vs.
placebo stress. At peak levels, participants reported ‘very slight’ negative affect. FTND
was not significantly related to negative affect (ps > .35).
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Positive

affect.

Positive

affect was measured via self-report
(PANAS) as part of the periodic
self-report

battery.

indicated

that

rmANOVA

positive

affect

exhibited no significant effects:
Time (p = .23), Dose (p = .91), or
Time X Dose interaction (p = .73;
Figure

4.22).

significantly
affect:

FTND

related
the

to

FTND

was
positive

X

Time

interaction was significant (F(3,51)
= 4.31, p < .01; partial η2 = 0.20
[moderate-to-large
Controlling

for

effect
FTND,

size]).
positive

affect decreased throughout each
experimental session, but did not
differ as a function of active vs.
placebo

stress

Participants

(ps

reported

>

.20).

‘moderate’

positive affect at baseline (peak
levels) and between ‘moderate’

Figure 4.21: Negative Affect (upper panel).
Figure 4.22: Positive Affect (lower panel).
Mean (± 1 SEM) self-reported affect is depicted for
the active stress (green line) and placebo sessions
(blue line). The approximate timing of each
experimental procedure is noted with arrows.
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and ‘a little’ positive affect at their
lowest levels.
4.2.5

Nicotine-seeking

and

Self-

and

self-

Administration
Nicotine-seeking
administration behavior.

Nicotine-

seeking

via

was

measured

the

choice (puffs vs. money) progressive
ratio task. Three participants were
excluded

from

nicotine-seeking

analyses for the following reasons.
Task instructions were explained
incorrectly to the first participant in
the study (experimenter error). One
participant
reduction

reported
in

a

significant

smoking

frequency

between study enrollment and the
experimental sessions (below study
inclusion thresholds; FTND < 4 and
<

10

cigarettes/day).

participant

switched

The
from

third

Figure 4.23 & 4.24: Placebo & Stress Puffs vs.
FTND. Cigarette puffs earned/smoked during the
placebo (upper panel) and stress (lower panel)
session are depicted by FTND score.

paper

cigarettes to e-cigarettes between study enrollment and experimental sessions. Thus,
nicotine-seeking analyses included 18 participants. The initial rmANOVA indicated that

72

nicotine-seeking did not differ as a
function of active vs. placebo stress
(p = .75; 5.3 ± 2.7 vs. 5.6 ± 2.4 puffs,
respectively). However, FTND was
significantly
seeking.

related
FTND

correlated

with

to

was

nicotinepositively

nicotine-seeking

during the placebo (Pearson = .60, p
< .01; Figure 4.23), but not active
stress session (Pearson = .11 p =
.67;

Figure

negatively

4.24).

FTND

was

with

the

correlated

Figure 4.25: Puffs Delta vs. FTND. Cigarette
puffs earned/smoked during the placebo minus
stress session are depicted by FTND score.

nicotine-seeking change score (puffs
earned

during the stress

minus

placebo session; Pearson = -.48, p <
.05; Figure 4.25). Including FTND in
the

model,

rmANOVA

indicated

significant Dose (F(1,16) = 4.93, p <
.05; partial η2 = 0.24 [large effect
size]) and Dose X FTND interaction
effects (F(1,16) = 4.83, p < .05;
partial η2 = 0.23 [large effect size]).
Relative to placebo, nicotine-seeking

Figure 4.26:
Nicotine-Seeking and SelfAdministration. Mean (± 1 SEM) cigarette
puffs earned and smoked for more (green
line) and less (blue line) nicotine dependent
participants (median split by FTND score) are
depicted for each experimental session.
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increased as a function of active stress, controlling for FTND. Moreover, median-split by
FTND, nicotine-seeking exhibited a significant Dose X FTND interaction (F(1,16) = 4.78,
p < .05; partial η2 = 0.23 [large effect size]) as a function of experimental session
(Figure 4.26). Relative to placebo, less dependent participants exhibited an increase in
nicotine-seeking during active stress (~1.5 puffs), while more dependent exhibited a
decrease in nicotine-seeking (~1.0 puff).
Nicotine
Nicotine

consumption

consumption

rate

rate.
was

measured, unbeknownst the participant,
as mean inter-puff interval (s) during
nicotine self-administration following the
nicotine-seeking task. Individuals with
valid choice data and who earned (and
smoked) at least two cigarette puffs (n =
16)

were

rmANOVA

included
indicated

in
that

analyses.
nicotine

consumption rate (log10-transformed) did
not differ as a function of active vs.

Figure 4.27: Nicotine Consumption Rate.
Mean (± 1 SEM) inter-puff interval (s) for
more (green line) and less (blue line) nicotine
dependent participants (median split by
FTND score) are depicted for each
experimental session.

placebo stress (p = .60; 27.5 ± 20.8s vs.
26.4 ± 14.9s, respectively; Figure 4.27). FTND was not significantly related to nicotine
consumption rate (p > .15).
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Figure 4.28: Geometric Voxel Overlap. Participant voxel placement was coregistered to
template space and orthonormal views depict geometric voxel overlap separately for each
voxel placement method. Percentage of geometric voxel overlap is indicated by color:
white indicates voxel space with complete overlap, while yellow/red indicate incomplete
overlap, across subjects.

4.2.6 Voxel Overlap
The voxel used in this study (location, dimensions, and rotation angles) was
identical to the 1H fMRS pilot study. AVP was used to prescribe voxel placement for a
subset of participants (AVP was under development at the onset of this study)
(Woodcock et al., 2017). Percentage of voxel overlap (with the template voxel) by voxel
placement method is described in
Table 4.3 and illustrated in Figure
4.28. Voxel overlap improved as AVP
became

functional.

Within-subject

voxel overlap across experimental

Table 4.3: Geometric Voxel Overlap. Mean
percentage (± 1 SD) of geometric voxel overlap
with the template voxel (i.e. placement
accuracy) is depicted by voxel placement
method.
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sessions (active vs. placebo stress)
was very good:
Voxel

tissue

31.8%

gray

87.3 ± 15.1%.
composition

and

66.0%

was

*

*

white

matter.
4.2.7 Letter 2-back Behavioral Data
Behavioral

data

were

unintelligible and discarded for 10
scans

(23.8%)

due

to

data

collection error. Behavioral data
demonstrated task compliance for
both the placebo (87.1 ± 13.3%
correct; 674 ± 233ms response
latency) and active stress (78.2 ±
15.1%

correct;

715

±

187ms

response latency) sessions. As a
function of experimental session
and

task

block,

rmANOVA

indicated that accuracy exhibited a
significant Time effect (F(4,48) =
6.61, p < .001; partial η2 = 0.36
[large effect size]; Figure 4.29),
generally improving across task

Figure 4.29:
Letter 2-back Response
Accuracy.
Figure 4.30: Letter 2-back Response Latency.
Mean (± 1 SEM) response accuracy (% correct;
upper panel) and latency (ms; lower panel) are
depicted across task blocks separately for the
active stress (green line) and placebo (blue line)
sessions. Paired t-test: *p < .05
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blocks during both experimental sessions (Placebo: Block 1 = 77.4 ± 19.2%, Block 5 =
90.5 ± 14.2%; Stress: Block 1 = 74.5 ± 12.0%, Block 5 = 74.5 ± 19.6%). Response
accuracy exhibited a significant Dose effect (F(1,12) = 6.35, p < .05; partial η2 = 0.35
[large effect size]), which indicated it was higher during placebo than active stress (87.1
± 13.3% vs. 78.2 ± 15.1%). Finally, a significant Time X Dose interaction (F(4,48) =
3.08, p < .05; partial η2 = 0.20 [moderate-to-large effect size]) indicated that response
accuracy improved more across task blocks during the placebo, relative to the active
stress session.
rmANOVA indicated that response latency exhibited a significant Time effect
(F(4,52) = 3.15, p < .05; partial η2 = 0.20 [moderate-to-large effect size]), but nonsignificant Dose (p = .89) and Time X Dose interaction effects (p = .56; Figure 4.30).
The significant Time effect indicated response latency generally decreased across task
blocks during both experimental sessions (Placebo: Block 1 = 739.2 ± 219.8ms, Block 5
= 655.7 ± 243.1ms; Stress: Block 1 = 788.8 ± 271.4ms, Block 5 = 672.8 ± 150.0ms).

Table 4.4: LCModel Fit Characteristics (32s). Mean (± 1 SD) LCModel fit
characteristics (32s; 8 avgs) are presented by task phase. GLU = glutamate; GLN
= glutamine; FWHM = full-width half-maximum; SNR = signal-to-noise; CRLB =
Cramer Rao Lower Bound.
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FTND was not significantly related to task accuracy or response latency (ps > .10).
4.2.8 LCModel Fit Characteristics (32s Resolution)
LCModel fit reliability was evaluated for 2-back A, 2-back B, and interleaved
fixation-cross rests for both experimental sessions. Four subjects were excluded from
outcome analyses due to
relatively poor LCModel fit
quality (greater than two SDs
worse

SNR

and

GLU

CRLB% relative to the group
mean). Importantly, LCModel
fit

characteristics

differ

as

a

did

function

not
of

experimental task (Task and
Task

X

Time

interaction

effects examined) during the
placebo session (Table 4.4;
upper

panel).

However,

during the stress session,
SNR and FWHM did differ as
a function of experimental
task (Table 4.4; lower panel).
FWHM was lower during 2back A relative to interleaved

Figure 4.31 & 4.32: Overall GLU Levels. Mean (± 1 SEM)
GLU levels during the placebo (upper panel) and stress
(lower panel) session are depicted.
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rest (Task effect; p < .05). SNR was higher during task (2-back A and B) relative to
interleaved rest (Task effects; ps ≤ .05).
4.2.9 Placebo GLU Modulation (32s Resolution)
The flashing checkerboard
minimized GLU fluctuation (mean
coefficient of variation percentage

**

= 6.1%) prior to 2-back (vs. rest)
modulation.
Placebo 2-back A vs. rest.
Overall GLU levels during 2-back
A were significantly higher (2.7%;
Figure

4.31)

than

interleaved

fixation-cross rest (F(1,83) = 8.12,
p

<

.01,

partial

η2 =

0.09

[moderate effect size]; 11.59 ±
1.05

vs.

11.29

±

0.93,

respectively; Figure 4.31). Across
task blocks, rmANOVA indicated
a marginal Task effect (F(1,16) =
4.01, p = .06, partial η2 = 0.20
[moderate-to-large

effect

size];

Figure 4.33), and non-significant
Time (p = .41) and Time X Task

Figure 4.33 & 4.34: Placebo 2-back A & B GLU
Levels (32s). Mean (± 1 SEM) 2-back A (upper
panel) and B (lower panel) GLU levels (32s; %
relative to interleaved fixation cross) during the
placebo session are depicted across task blocks.
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interaction effects (p = .19). 2-back A GLU levels were higher than interleaved fixationcross levels (especially in later task blocks).
Placebo 2-back B vs. rest. Overall GLU levels during 2-back B did not differ from
interleaved fixation-cross rest (p
= .67; 11.25 ± 1.04 vs. 11.29 ±
0.93, respectively; Figure 4.31).
Across task blocks, rmANOVA
indicated no significant effects:
Time (p = .65), Task (p = .71),
and Time X Task interaction (p =
.17; Figure 4.34).
4.2.10 Stress GLU Modulation
(32s Resolution)
The

flashing

checkerboard

minimized

GLU

fluctuation (mean coefficient of
variation percentage = 5.7%)
prior

to

2-back

(vs.

rest)

modulation.
Stress 2-back A vs. rest.
Overall GLU levels during 2-back
A were not significantly different
from

interleaved fixation-cross

Figure 4.35 & 4.36: Stress 2-back A & B GLU
Levels (32s). Mean (± 1 SEM) 2-back A (upper
panel) and B (lower panel) GLU levels (32s; %
relative to interleaved fixation cross) during the
stress session are depicted across task blocks.
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rest (p = .58; 11.35 ± 1.03 vs. 11.42 ± 0.98, respectively; Figure 4.32). Across task
blocks, rmANOVA indicated no significant effects: Time (p = .45), Task (p = .59), and
Time X Task interaction (p = .18; Figure 4.35).
Stress 2-back B vs. rest. Overall GLU levels during 2-back B did not differ from
interleaved fixation-cross rest (p = .22; 11.27 ± 0.90 vs. 11.42 ± 0.98, respectively;
Figure 4.32). Across task blocks, rmANOVA indicated no significant effects: Time (p =
.44), Task (p = .26), and Time X Task interaction (p = .14; Figure 4.36).
4.2.11 BOLD Effect (32s Resolution)
Relative to interleaved fixation-cross rest, rmANOVA indicated spectral linewidth
(FWHM) was significantly more narrow for 2-back A during the active stress (Task
effect: F(1,16) = 5.30, p < .05; Time X Task interaction effect: p = .99), but not the
placebo session (ps > .05). rmANOVA indicated no effect for task on FWHM for 2-back
B for either session (ps > .06).
4.2.12 Neurochemical Specificity (32s Resolution)
During the placebo session, metabolites (PCr+Cr, GPC+PC, Myo-Inositol, and
NAA) did not significantly differ as a function of task (2-back A and B vs. interleaved
fixation-cross rest; ps ≥ .09).
During the active stress session, Myo-Inositol exhibited significant Task and
Time X Task interaction effects (F(1,16) = 6.18, p < .05 and F(4,64) = 2.60, p < .05,
respectively). Interleaved fixation-cross rest Myo-Inositol levels were higher than 2-back
A levels, but tended to converge in later task blocks. GPC+PC exhibited a significant
Task effect (F(1,16) = 9.56, p < .01). GPC+PC levels during rest were generally higher
than 2-back A levels across task blocks. NAA and PCr+Cr did not differ as a function of
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task (ps > .10). LCModel quantification of NAA levels was not biased by the significant
BOLD effect (i.e. narrow spectral linewidth did not significantly alter area-under-thecurve quantification).
4.2.13 LCModel Fit Characteristics (64s Resolution)
As anticipated, 64s temporal resolution (16 avgs) was associated with more
reliable LCModel fit, relative to 32s (8 avgs) resolution. LCModel fit characteristics
described in Table 4.5. Importantly, LCModel fit characteristics did not significantly

Table 4.5:
LCModel Fit Characteristics (64s). Mean (± 1 SD) LCModel fit
characteristics (64s; 16 avgs) are presented by task phase. GLU = glutamate; GLN =
glutamine; FWHM = full-width half-maximum; SNR = signal-to-noise; CRLB = Cramer
Rao Lower Bound.

differ as a function of task for the placebo session (ps > .08). However, consistent with
32s resolution, SNR differed as a function of task during the stress session (2-back A >
rest; p < .01).
4.2.14 Placebo GLU Modulation (64s Resolution)
Placebo 2-back A vs. rest. Across task blocks, rmANOVA indicated a significant
Time X Task interaction (F(3,48) = 2.80, p = .05, partial η2 = 0.15 [moderate-to-large
effect size]), but non-significant Time (p = .44) and Task effects (p = .59). 2-back A GLU
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levels were significantly higher than interleaved fixation-cross levels in later task blocks
(Figure 4.37).
Placebo 2-back B vs. rest.

Across task blocks, rmANOVA indicated no

significant effects: Time (p = .51), Task (p = .19), and Time X Task interaction (p = .30)
(Figure 4.38).

**

Figure 4.37 & 4.38: Placebo 2-back A & B GLU
Levels (64s). Mean (± 1 SEM) 2-back A (upper
panel) and B (lower panel) GLU levels (64s; %
relative to interleaved fixation cross) during the
placebo session are depicted across task blocks.

Figure 4.39 & 4.40: Stress 2-back A & B GLU
Levels (64s). Mean (± 1 SEM) 2-back A (upper
panel) and B (lower panel) GLU levels (64s; %
relative to interleaved fixation cross) during the
stress session are depicted across task blocks.
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4.2.15 Stress GLU Modulation (64s Resolution)
Stress 2-back A vs. rest. Across task blocks, rmANOVA indicated no significant
effects: Time (p = .90), Task (p = .54), and Time X Task interaction (p = .18) (Figure
4.39).
Stress 2-back B vs. rest. Across task blocks, rmANOVA indicated no significant
effects: Time (p = .99), Task (p = .24), and Time X Task interaction (p = .08) (Figure
4.40).
4.2.16 BOLD Effect (64s Resolution)
rmANOVA indicated spectral linewidth (FWHM) did not significantly differ as a
function of task (2-back vs. rest) for the placebo or stress sessions (ps > .20).
4.2.17 Neurochemical Specificity (64s Resolution)
During the placebo session, NAA exhibited a significant Time X Task interaction
effect (F(3,48) = 3.24, p < .05), but not a Task effect. NAA levels during interleaved
fixation-cross rest were higher than 2-back B, but only in later task blocks. No
significant effect for NAA during 2-back A. Consistent with the 32s temporal resolution
findings, other metabolites (PCr+Cr, GPC+PC, and Myo-Inositol) did not significantly
differ as a function of task (2-back A and B vs. interleaved fixation-cross rest; ps ≥ .10).
Consistent with findings at 32s temporal resolution, Myo-Inositol and GPC+PC
differed as a function of task during the active stress session. Myo-Inositol exhibited
significant Task and Time X Task interaction effects (F(1,17) = 15.92, p < .001 and
F(3,51) = 2.79, p = .05, respectively). Interleaved fixation-cross rest Myo-Inositol levels
were higher than 2-back A levels, especially in later task blocks. GPC+PC exhibited
significant Task effects for 2-back A and B (F(1,17) = 13.02, p < .01; F(1,17) = 4.57, p <
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.05; respectively). GPC+PC levels during rest were higher than 2-back A and B levels
across task blocks. NAA and PCr+Cr did not differ as a function of task (ps > .10).
4.2.18 Cerebrovascular Reactivity
Second-level contrasts (breath hold > paced breathing) revealed significant
clusters (voxel-level; p < .05) during both the placebo and active stress sessions (Figure
4.41). Significant clusters were found throughout the cortex (primarily in gray matter)
during both sessions. Experimental sessions were contrasted (placebo > stress and
stress > placebo) to produce CVR difference maps (Figure 4.42). CVR difference maps
identified clusters that significantly differed (voxel-level; p < .05) as a function of
vascular reactivity between sessions, and thus, may confound between-session
contrasts of interest. Therefore, CVR difference maps were subtracted from betweensession contrasts of interest to reduce the likelihood of false positives.
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Figure 4.41: Cerebrovascular Reactivity Maps. Cerebrovascular reactivity maps
(voxel-wise p < .05; breath hold > paced breathing) are depicted on contiguous axial
slices for placebo (upper panel) and active stress (lower panel). Lighter color reflects
greater cerebrovascular reactivity.
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Figure 4.42: Cerebrovascular Reactivity Difference Maps. Cerebrovascular reactivity
difference maps (voxel-wise p < .05) are depicted on contiguous axial slices
contrasting sessions: placebo > stress (upper panel) and stress > placebo (lower
panel). Lighter color reflects greater cerebrovascular reactivity.
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4.2.19 Letter 2-back fMRI Data
Letter 2-back behavioral data. Behavioral data demonstrated task compliance
during the letter 2-back fMRI task. Response accuracy was non-significantly higher
during placebo, relative to active stress (p = .11; 89.9 ± 13.9% vs. 84.7 ± 14.9%,
respectively).
Letter 2-back > fixation-cross rest.

As hypothesized, cluster-level corrected

images (p < .05) revealed significant bilateral activation in the dlPFC during 2-back task
performance (> fixation-cross rest) during both experimental sessions (Figure 4.43).
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Figure 4.43: Letter 2-back Activation Maps. Cluster-level corrected (p < .05) letter 2back (> fixation cross rest) activation maps are depicted on contiguous axial slices
for the placebo (upper panel) and stress session (lower panel). Lighter color reflects
more BOLD activation.

Stress > placebo: letter 2-back > rest. Contrary to hypotheses, bilateral dlPFC
clusters survived cluster-level and CVR difference map correction for stress > placebo
(Figure 4.44). These clusters demonstrated that letter 2-back task performance elicited
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greater BOLD activation during active stress, relative to placebo. Significant clusters in
the insula suggest participants processed peripheral signals that may be attributed to
physiological effects of the stress manipulation (elevated BP, etc.).
Placebo > stress: letter 2-back > rest. The converse comparison revealed one
significant cluster (mPFC; Figure 4.44). These results demonstrated that 2-back
performance elicited a relatively smaller BOLD response during placebo relative to
active stress. Participants exhibited non-significantly higher response accuracy, but
smaller dlPFC BOLD response during placebo, relative to active stress.
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Figure 4.44: Letter 2-back Difference Maps. Cluster-level corrected (p < .05) letter
2-back (> fixation cross rest) difference maps are depicted on contiguous axial
slices: placebo > stress (upper panel) and stress > placebo (lower panel). Lighter
color reflects more BOLD activation.

Letter 2-back > rest: median-split by FTND. Exploratory analyses examined the
BOLD response during letter 2-back by splitting the sample into two groups: mediansplit by FTND. These analyses paralleled the nicotine-seeking and self-administration
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data. Less dependent participants exhibited less dlPFC neural engagement (less BOLD
activation) during 2-back performance in the stress session (relative to placebo; Figure
4.45). Conversely, more dependent participants engaged their dlPFC more during 2back performance in the stress session (relative to placebo).
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Figure 4.45: Letter 2-back Maps by Nicotine Dependence. Cluster-level corrected
(p < .05) letter 2-back (> fixation cross rest) difference maps median split by
FTND score are depicted on contiguous axial slices: less (upper panel) and more
nicotine dependent (lower panel) stress > placebo. Lighter color reflects more
BOLD activation.
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4.2.20 Cued N-back Behavioral
Data
fMRI
smoking

vs.

behavioral

data:

neutral

cued.

Accuracy and response latency
were evaluated across N-back
levels (0-, 1-, and 2-back) and
by image type (smoking vs.
neutral) for both experimental
sessions.
Neutral

images.

rmANOVA indicated response
accuracy decreased as N-back
task difficulty increased (0-back
= 94.3 ± 10.9%; 2-back = 64.1 ±
19.5%)

for

neutral

images

across experimental sessions
(N-back effect: F(2,26) = 31.57,
p < .001; partial η2 = 0.71 [very
large effect size]; Figure 4.46).
There

was

no

effect

of

experimental session on neutral
image

response

accuracy

Figure 4.46 & 4.47: Neutral N-back Response
Accuracy and Response Latency. Mean (± 1
SEM) response accuracy (% correct; upper
panel) and response latency (ms; lower panel)
for neutral images during the placebo (blue line)
and active stress session (green line) are
depicted across N-back levels.
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across N-back levels (Dose effect:
p = .14; N-back X Dose interaction:
*

p = .82).
For

neutral

images,

response latency decreased as Nback difficulty increased (N-back
effect: F(2,26) = 13.40, p < .001;
partial η2 = 0.51 [very large effect
size]; 0-back = 649.3 ± 231.7ms; 2back = 449.8 ± 193.8ms; Figure
4.47). Response latency was not
differentially

affected

by

experimental session across Nback levels (Dose effect: p = .73;
N-back X Dose interaction:

p =

.69).
Smoking images. rmANOVA
indicated response accuracy nonsignificantly decreased as N-back
difficulty increased (0-back = 95.8 ±
10.4%; 2-back = 91.1 ± 13.4%) for
smoking

images

experimental

across

sessions

both

(N-back

Figure 4.48 & 4.49: Smoking N-back Response
Accuracy and Response Latency. Mean (± 1
SEM) response accuracy (% correct; upper
panel) and response latency (ms; lower panel)
for smoking images during the placebo (blue
line) and stress session (green line) are
depicted across N-back levels. Paired t-test: *p
< .05
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effect: F(2,26) = 3.08, p = .06;
partial η2 = 0.19 [moderate-tolarge effect size]; Figure 4.48).
There

was

experimental
smoking

no

effect

session

image

*

of
on

response

accuracy across N-back levels
(Dose effect: p = .47). However,
a significant N-back X Dose
interaction (F(2,26) = 8.24, p <
.01; partial η2 = 0.39 [very large
effect size]) indicated response
accuracy decreased more as Nback difficulty increased during
the placebo session (relative to

*
*

the stress session).
For

smoking

images,

response latency increased as
N-back difficulty increased (Nback effect: F(2,26) = 3.69, p <
.05; partial η2 = 0.22 [moderateto-large effect size]; 0-back =
556.4 ± 191.4ms; 2-back =

Figure 4.50 & 4.51: Placebo N-back Response
Accuracy and Response Latency. Mean (± 1
SEM) response accuracy (% correct; upper
panel) and response latency (ms; lower panel)
during the placebo session are depicted by
image type (neutral: blue line vs. smoking: green
line) across N-back levels. Paired t-test: *p < .05
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602.3 ± 231.7ms; Figure 4.49). Response latency was not differentially affected by
experimental session across N-back levels (Dose effect:

p = .33; N-back X Dose

interaction: p = .46).
Neutral vs. smoking images: placebo session. rmANOVA indicated response
accuracy significantly decreased as N-back difficulty increased (0-back = 99.4 ± 3.2%;
2-back = 76.8 ± 20.0%) for both image types (N-back effect: F(2,26) = 22.05, p < .001;
partial η2 = 0.63 [very large effect size]; Figure 4.50). There was no effect of image type
on response accuracy across N-back levels (Image effect:

p = .38). However, a

significant N-back X Image interaction (F(2,26) = 10.98, p < .001; partial η2 = 0.46 [very
large effect size]) indicated response accuracy decreased less for smoking images as
N-back difficulty increased, relative to neutral images.
rmANOVA indicated response latency non-significantly decreased as N-back
difficulty increased (N-back effect: F(2,26) = 2.91, p = .07; partial η2 = 0.18 [moderateto-large effect size]; 0-back = 580.6 ± 178.8ms; 2-back = 489.9 ± 220.1ms; Figure
4.51). Response latency did not differ across N-back levels as a function of image type
(Image effect: p = .43). However, a significant N-back X Image interaction (F(2,26) =
6.43, p < .01; partial η2 = 0.33 [very large effect size]) indicated response latency
decreased more for neutral images as N-back difficulty increased, relative to smoking
images.
Neutral vs. smoking images:

stress session.

rmANOVA indicated response

accuracy significantly decreased as N-back difficulty increased (0-back = 91.7 ± 12.9%;
2-back = 78.2 ± 22.8%) for both image types (N-back effect: F(2,34) = 16.23, p < .001;
partial η2 = 0.49 [very large effect size]; Figure 4.52). A main effect of image type across
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N-back levels (F(1,17) = 20.12, p <
.001; partial η2 = 0.54 [very large
*

effect

size])

participants

indicated
responded

that
more

accurately for smoking vs. neutral
images. In addition, a significant Nback X Image interaction (F(2,34) =
17.18, p < .001; partial η2 = 0.50
[very large effect size]) indicated
that accuracy decreased less for
smoking images (relative to neutral
images)

as

N-back

difficulty

increased.
rmANOVA

indicated

response

latency

decreased

as

*

significantly

N-back

difficulty

increased (N-back effect: F(2,34)
= 4.39, p < .05; partial η2 = 0.21
[moderate-to-large effect size]; 0back = 603.4 ± 202.9ms; 2-back =
528.0 ± 173.0ms; Figure 4.53).
Response latency did not differ
across N-back levels as a function

Figure 4.52 & 4.53: Stress N-back Response
Accuracy and Response Latency. Mean (± 1
SEM) response accuracy (% correct; upper
panel) and response latency (ms; lower panel)
during the stress session are depicted by image
type (neutral: blue line vs. smoking: green line)
across N-back levels. Paired t-test: *p < .05
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of image type (Image effect:

p = .94). However, a significant N-back X Image

interaction (F(2,34) = 11.65, p < .001; partial η2 = 0.41 [very large effect size]) indicated
that response latency decreased more for neutral images as N-back difficulty
increased, relative to smoking images.
4.2.21 Cued N-back fMRI Data
0-back fMRI activation. One subject was excluded from all fMRI BOLD activation
analyses that contrasted image type (smoking vs. neutral) because he switched to ecigarettes and reported paper cigarettes were aversive. BOLD activation analyses
focused on the effect of image type (smoking > neutral and neutral > smoking) across
N-back levels (0-, 1-, and 2-back; Figure 4.54). During the placebo session, 0-back
BOLD response was contrasted by image type. Smoking images elicited greater BOLD
response in the amygdala, mPFC, mOFC, and ventral striatum, relative to neutral
images. Activation in these regions is often attributed to drug cue salience and/or
appetitive motivation. Interestingly, a few clusters in the dlPFC were activated during
smoking > neutral cues. The 0-back is an attentional control task and does not
substantially engage working memory processes (i.e. dlPFC). Thus, it was plausible
that dlPFC activation was associated with network interactions with the mOFC and/or
mPFC.
Notably, during the stress session, smoking cues did not elicit the same degree
of BOLD response in the mPFC, mOFC, and ventral striatum. A few small clusters in
the striatum and one in mOFC/mPFC survived cluster-level correction. These findings
were contrary to a priori hypotheses.
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Figure 4.54: Cued 0-back fMRI Activation Maps. Cluster-level corrected (p < .05)
activation maps during 0-back (smoking > neutral images) are depicted on
contiguous axial slices for the placebo (upper panel) and stress session (lower
panel). Lighter color reflects more BOLD activation.
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1-back fMRI activation. During both experimental sessions, smoking > neutral
images elicited robust activation across the network of interest at the 1-back level
(Figure 4.55). During placebo, widespread BOLD activation was elicited in the
amygdala, mOFC, mPFC, ventral and dorsal striatum, dPFC, dlPFC, dACC, and
superior parietal lobule. During the stress session, clusters were found throughout the
striatum and PFC, but not in the mOFC or superior parietal lobule. Similar to the 0-back
findings, smoking images elicited greater BOLD activation in reward network regions
during placebo, relative to the active stress.
2-back fMRI activation. During placebo, subtle BOLD effects were observed in
the mOFC, mPFC, and striatum for smoking > neutral images (Figure 4.56). During
stress, BOLD activation was limited to three clusters: mOFC, dorsal striatum, and
dorsal PFC. Task difficulty (2-back) may have diminished the salience of the smoking
images (relative to neutral images). Individuals may have been preoccupied with task
performance at the expense of image salience. Notably, smoking images were
associated with higher response accuracy (> neutral images) across experimental
sessions.
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Figure 4.55: Cued 1-back fMRI Activation Maps. Cluster-level corrected (p < .05)
activation maps during 1-back (smoking > neutral images) are depicted on
contiguous axial slices for the placebo (upper panel) and stress session (lower
panel). Lighter color reflects more BOLD activation.
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Figure 4.56: Cued 2-back fMRI Activation Maps. Cluster-level corrected (p < .05)
activation maps during 2-back (smoking > neutral images) are depicted on
contiguous axial slices for the placebo (upper panel) and stress session (lower
panel). Lighter color reflects more BOLD activation.

Overall fMRI activation. BOLD activation associated with smoking cues (smoking >
neutral images) across all N-back levels were contrasted by experimental session
(Figure 4.57). For placebo > stress, robust BOLD activation was observed in the ventral
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and dorsal striatum, mPFC, mOFC, dlPFC, dPFC, dACC, and superior parietal lobule.
Notably, large clusters in the mOFC and mPFC were identified and may be attributed to
salience of smoking (> neutral) images, independent of task difficulty. For stress >
placebo, one small cluster was observed (mPFC/dACC). Smoking images elicited a
more robust BOLD response in the placebo, relative to the stress, session, contrary to a
priori hypotheses.
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Figure 4.57: Image Effect Difference Maps. Cluster-level corrected (p < .05)
difference activation maps across N-back levels (smoking > neutral images) are
depicted on contiguous axial slices: placebo > stress (upper panel) and stress >
placebo (lower panel). Lighter color reflects more BOLD activation.

4.2.22 fMRI vs. 1H fMRS
Exploratory analyses investigated statistical relationships between 1H fMRS GLU
levels and BOLD fMRI response during the letter 2-back task. Using each subject’s 1H
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fMRS voxel as a mask, Z scores (peak activation) and peak cluster extents were
extracted from BOLD contrasts (letter 2-back > fixation-cross) at the same temporal
resolution (32s; 2-back A and B) as 1H fMRS analyses. This strategy resulted in two
correlation matrices: Z scores and cluster extents. Each matrix contained four rows of
fMRI metrics (2-back A and B X 2 task repetitions) by eight columns of 1H fMRS GLU
levels (first 1H fMRS task block was excluded [practice effect]; 2-back A and B X 4 task
repetitions) for a total of 32 matrix cells. Bivariate Pearson correlations were used to
examine statistical relationships with a liberal threshold (p ≤ .10). During the placebo
session, 7 of 32 cells (21.9%) were positively correlated for fMRI Z scores and 5 of 32
cells (15.6%) were positively correlated for fMRI cluster extents. During the stress
session, 1 cell (3.1%) was negatively correlated for fMRI Z scores and none were
correlated for fMRI cluster extents.
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CHAPTER 5 DISCUSSION
5.1 1H fMRS Pilot Study Discussion
5.1.1 1H fMRS Pilot Study Results Overview
The goals for the pilot study were three-fold:

1) develop and evaluate an

automated method for accurate and reliable single voxel placement, 2) develop a
working memory 1H fMRS paradigm, and 3) quantify GLU levels during working memory
task performance. Our results demonstrated that: automated voxel placement (AVP)
method was highly accurate and reliable; the working memory paradigm was feasible;
LCModel quantification of metabolite levels at 32s temporal resolution (8 avgs) was
reliable; and left dlPFC GLU levels were modulated during working memory task
performance. To the best of our knowledge, this was the first study in human subjects
that demonstrated dlPFC GLU levels were significantly modulated during working
memory task performance. This study validated a novel biomarker of dlPFC cognitive
task engagement that is not confounded by vasoactive medications or subject-level
differences in cardiovascular health (e.g. aging or chronic substance abuse [cigarette
smoking]).
Healthy,

medication-free,

and

well-educated

right-hand-dominant

college

students (N = 16) narrowly selected for age were recruited to participate in a brief pilot
study. Participants were instructed to perform two behavioral tasks during continuous in
vivo single voxel

1

H MRS spectra acquisition (Figure 3.1). During the first task

(continuous fixation-cross), participants were instructed to focus their visual gaze on a
static fixation-cross, relax, and let their thoughts drift. The second task (letter 2-back)
included two phases. During phase one, participants were instructed to focus their
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visual gaze on a flashing checkerboard (3Hz), relax, and let their thoughts drift. Pilot
research in our laboratory demonstrated that flashing checkerboard stabilized GLU
levels (minimized variance) more effectively than other stabilization paradigms
(unpublished data). During phase two, participants were instructed to complete a letter
2-back task with interleaved blocks of fixation-cross rest. The letter 2-back task is a
well-established working memory paradigm. A meta-analysis of letter 2-back fMRI
studies demonstrated that task performance was consistently associated with bilateral
dlPFC BOLD activation (Owen et al., 2005).
Behavioral data demonstrated that participants were task compliant. Mean letter
2-back response accuracy was high across task blocks (mean accuracy: 94.8% ±
10.7%; mean response latency: 644 ± 171ms). Response accuracy significantly
increased across task blocks (from 88.5% in block 1 to 96.9% in block 7; Figure 4.2).
5.1.2 Automated Voxel Placement (AVP)
As part of my graduate training, we developed and evaluated an automated
voxel placement (AVP) method to address a frequently over-looked source of error
variance

in

single-voxel

magnetic

resonance

spectroscopy

research

studies:

inconsistent voxel placement. It is well-established that neurochemistry varies by
anatomical region and voxel tissue composition (gray vs. white matter) (Erecińska &
Silver, 1990; Pouwels & Frahm, 1998). Therefore, inconsistent voxel placement across
research subjects (or longitudinally within subjects) increases likelihood of Type I and II
error. Three Linux- and Matlab-based scripts were developed:

avp_create,

avp_coregister, and avp_overlap. Avp_create facilitated creation of a library of voxel
locations in template space prior to subject scanning. At the scanner, avp_coregister
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automatically coregistered the template voxel to the current research subject based on
his/her head position in the scanner (T 1-weighted image; Figure 3.3). At the end of a
research study, avp_overlap will extract voxel location information from each subject’s
.rda file (ASCII file created during MRS spectra acquisition), re-create the voxel in
subject space, coregister the voxel to template space, and calculate voxel tissue
composition, geometric voxel overlap with the template voxel (i.e. voxel placement
accuracy) and geometric voxel overlap across research subjects (i.e. voxel placement
reliability). AVP was developed and tested for human brain imaging research on a 3T
Siemens Verio system. However, AVP was programmed to be scanner system-, field
strength-, anatomy- and subject population-independent.
AVP was used to prescribe voxels for 15 of the 16

1

H fMRS pilot study

participants (AVP not used for one subject; experimenter error). Voxel placement
accuracy (mean geometric voxel overlap with the template location = 93.2%) and
reliability (mean geometric voxel overlap across all participants = 89.9%; Figure 4.1)
were excellent. Mean voxel tissue composition was 36.8 ± 3.8% gray and 60.8 ± 4.5%
white matter.
5.1.3 GLU Modulation
LCModel fit and metabolite quantification was 100% automated. LCModel fit and
GLU quantification at 32s resolution (8 avgs) was reliable (Table 4.1). Importantly,
LCModel fit quality did not differ as a function of experimental task. Results from this
pilot study demonstrated that GLU levels were modulated during working memory task
performance. Relative to continuous fixation-cross rest, left dlPFC GLU levels were
significantly higher (3.4%) during the first 32s of letter 2-back task performance (2-back
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A) across seven task blocks (Figure 4.5). Similarly, the final 32s of letter 2-back task
performance (2-back B) were elevated (2.9%), but non-significantly higher (p = .07)
than continuous fixation-cross rest (Figure 4.5). These findings demonstrated, for the
first time in human subjects, that working memory task performance increased in vivo
dlPFC GLU levels.
Relative to interleaved fixation-cross rest, results were more complicated. 2back A and B exhibited significant Time X Task interactions relative to interleaved
fixation-cross rest (Figures 4.7, 4.10, and 4.11). GLU levels were higher during initial
task blocks, but lower during middle task blocks. These findings indicate that working
memory task performance was associated with elevated GLU levels, but the effect was
time-limited. Significant Time effects indicated that GLU levels generally increased
across task blocks. We speculated that 2-back task performance became routine and
unchallenging for this well-educated sample. Evidence to support this assertion was
twofold: 1) response accuracy significantly increased across task blocks (nearly perfect
response accuracy after the initial task block), and 2) GLU levels significantly increased
across task blocks. A significant increase in GLU levels across task blocks suggested
participants engaged their dlPFC during 2-back and during interleaved fixation-cross
rest – thus, participants were not truly ‘resting.’ As participants demonstrated task
mastery, their attention may have drifted during the interleaved rest blocks, instead of
‘resting.’ The dlPFC is involved in numerous cognitive processes – directed attention,
rumination, and executive control of lower structures – any of which could have
modulated GLU levels. Future studies will investigate an interleaved 0-back attention
control task, instead of the interleaved fixation-cross used herein.
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The 1H fMRS signal is a direct measurement of in vivo GLU molecules from all
sources within the voxel. The 1H fMRS signal does not differentiate cell types (pre- vs.
post-synaptic neurons or glia) or compartments (intracellular vs. extracellular). Results
presented herein demonstrated that GLU concentration (i.e. total number of GLU
molecules within the voxel location) was higher during letter 2-back, relative to fixationcross rest. We interpret these findings as follows: task-related cognitive demand (i.e.
increased neural activity) resulted in increased metabolic activity in the dlPFC, which
was measured herein as elevated GLU levels. The literature and limitations of the
approach provided context for interpretation of these data.
A series of well-controlled studies spanning decades at Yale University
demonstrated that neuronal spiking frequency increased in the dlPFC during a spatial
working memory task in non-human primates (Goldman-Rakic, 1995). Using the same
experimental approach, Arnsten and colleagues demonstrated that spatial working
memory was associated with persistent excitatory microcircuits (“delay” cells; primarily
mediated via GLU molecules binding NMDA NR2B receptor subunits) in layer III of the
cortex (Wang et al., 2013). These microcircuits are thought to maintain memory traces
during the delay period (time period between the presentation of stimulus and the target
[i.e. blank screen]) such that the primate can respond accurately (Wang et al., 2013).
These studies demonstrated that working memory task performance was associated
with persistent neural activity, mediated via glutamatergic synapses, in the dlPFC.
However, it is unlikely the signal measured in the present study reflected GLU
molecules involved in excitatory neurotransmission. Evidence to support this assertion
was two-fold: 1) low extracellular GLU concentration and 2) synaptic GLU time scale.
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Intracellular GLU concentration is approximately 10 mM (Erecińska & Silver, 1990),
whereas extracellular and cerebrospinal GLU concentrations are 0.5-1.0 μM and 1-10
μM, respectively (Schousboe, Bak, Sickmann, Sonnewald, & Waagepetersen, 2007).
Thus, the overwhelming majority of the 1H fMRS GLU signal was intracellular (~103
higher concentration than extracellular). Thus, even a 50% increase in synaptic GLU
concentration would only increase total 1H fMRS-measured GLU by ~0.0014%. In
addition, extracellular GLU molecules are present in the synapse for < 5ms before
binding transporters, ion-channels, or G-protein coupled receptors. If the first RF pulse
(in the PRESS sequence) excited a GLU molecule traversing the synapse, it is likely the
magnetization would be negated when that GLU molecule bound a receptor or
transporter before digitization of the signal (TE = 23ms). Therefore, although GLU is the
primary excitatory neurotransmitter and previous work found that working memory is
mediated via cortical glutamatergic microcircuits in the dlPFC, it is unlikely the signal
measured herein reflects GLU molecules involved in neurotransmission. Rather, the
overwhelming majority of signal measured in this study was associated with GLU
molecules found in pre-synaptic vesicles, circulating as neurochemical intermediates for
other neurotransmitters (GABA and glutamine), or as an anaplerotic substrate of the
TCA cycle. Fortunately, interpretation of the present data is informed by prior research,
which demonstrated GLU concentration scaled with neural activity: increased neural
activity was associated with increased GLU levels (Mangia et al., 2006; Schaller et al.,
2013; Schaller et al., 2014). Elevated neuronal activity is coupled with elevated glucose
extraction and metabolism that should result in elevated GLU levels from all sources
measured via 1H fMRS. Extensive

13

C MRS research demonstrated GLU-glutamine
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neurotransmission cycling rate was tightly coupled with oxidative metabolism in awake
and anesthetized rodents (Douglas L Rothman, De Feyter, Graaf, Mason, & Behar,
2011; D. L. Rothman, De Feyter, Maciejewski, & Behar, 2012). A nearly 1:1 relationship
indicated that for every molecule of GLU released into the synapse and recycled to the
presynaptic neuron as glutamine, approximately one molecule of glucose was
metabolized in the TCA cycle (Douglas L Rothman et al., 2011). In other words,
elevated spiking activity and excitatory neurotransmission corresponded with elevated
metabolic activity to support cellular energy demands (e.g. restoration of ion
concentration gradients and metabolic intermediates). Thus, the GLU signal measured
in this study likely reflected GLU molecules involved in metabolic events associated with
excitatory neurotransmission driven by working memory task performance. Our findings
were consistent with previous 1H fMRS studies that demonstrated elevated GLU levels
(~2-4%) during neural activity (Mangia et al., 2006; Schaller et al., 2013; Schaller et al.,
2014) and a meta-analysis of fMRI studies that found neural activity in the dlPFC was
consistently elevated during 2-back task performance (Owen et al., 2005).
5.1.4 Limitations and Alternative Explanations
This pilot study had a number of important limitations. First, as is the case with
all single voxel MRS studies, this study was susceptible to partial volume effects. Three
factors minimized the influence of partial volume effects on these findings. Voxel
placement reliability was excellent (mean geometric voxel overlap across subjects =
89.9%) which minimized partial volume effects. Moreover, tissue voxel composition
variability was low across subjects (gray and white matter coefficient of variation
percentage was 10.3% and 7.4%, respectively) and included in the calculation of GLU
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concentration. Finally, outcome analyses were limited to within-subject comparisons
(i.e. GLU levels contrasted by experimental task). Therefore, it was unlikely partial
volume effects influenced study findings. Second, we were unable to reliably quantify
other relevant neurotransmitters (e.g. GABA and glutamine) due to SNR limitations in
the present study. Future studies could use higher field strengths, lower temporal
resolution (e.g. more averaging), or other sequences (e.g. MEGA-PRESS) to
investigate task-related modulation of GABA and glutamine levels.
There were several alternative explanations for task-related modulation of GLU
levels in the dlPFC. First, as reported in other 1H fMRS studies, there was possibility of
a BOLD effect (Mangia et al., 2006; Schaller et al., 2013; Schaller et al., 2014).
Increased neural activity will increase concentration of oxygenated blood (oversupply of
oxygenated hemoglobin relative to oxygen extraction; BOLD effect) which can influence
T2* and spectral linewidth. A BOLD effect would result in narrow metabolite peaks
(FWHM). Inconsistent with prior studies, we found no evidence of a significant BOLD
effect on FWHM (Task and Time X Task interaction ps > .10). Moreover, LCModel
should be robust to the influence of spectral linewidth on metabolite level quantification.
Indeed, during 2-back A, no metabolites differed as a function of experimental task
other than GLU. Second, GLU’s transverse relaxation (T2*) could have changed as a
result of task performance. The equation

describes the relationship

between the initial signal (S0), the measured signal (S), echo time (TE), and transverse
magnetization (T2). To explain the observed effects (task-related GLU levels increased
2.9-3.4% relative to continuous fixation-cross rest), transverse relaxation (T2*) would
need to increase > 30% (GLU T2 = ~200ms at 3T in the dlPFC (Choi et al., 2006)). Prior
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studies indicated T2* changes alone are unlikely to explain the observed data (Ogawa
et al., 1992). Third, Type I error is possible. However, evidence against this explanation
was three-fold: 1) results reported herein were consistent with fMRI, fMRS, and
electrophysiology literature; 2) the experimental design was carefully selected to
mitigate Type I error (e.g. use of a stabilization task [flashing checkerboard], two rest
comparison conditions, cognitively-healthy and unmedicated sample, high task
compliance, and reliable voxel placement), and 3) moderate effect size (i.e. study was
not ‘over-powered’). Fourth, LCModel fit quality could have been biased and ‘over-fit’
GLU levels during 2-back task performance, relative to rest. This was also unlikely.
Individual raw spectra were phase- and shift-corrected prior to averaging and LCModel
fit (using a 100% automated procedure). Moreover, LCModel fit characteristics (FWHM,
SNR, GLU CRLB% and GLN CRLB%) did not differ as a function of experimental task
(Table 4.1). Finally, LCModel fit of GLU was reliable (GLU CRLB ~7 ± 1%) across task
and rest conditions.
5.1.5 1H fMRS Pilot Study Results Summary
In summary, this pilot study demonstrated that AVP was an accurate and reliable
method of automated voxel placement, LCModel reliably fit 1H fMRS spectra and
quantified GLU levels at a cognitive task-relevant time scale (32s; 8 avgs), and letter 2back task performance modulated GLU levels in the left dlPFC, relative to fixation-cross
rest. These data validated an in vivo biomarker of cognitive task-related neural
engagement. To our knowledge, this was the first demonstration of working memory
task-related modulation of GLU levels in humans. However, to date, similar studies
using 1H fMRS found cognitive task- or sensory stimulation-related GLU modulation in a
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variety of brain regions, including: dlPFC, hippocampus, occipital lobe, and motor
cortex. The value of this novel biomarker is twofold: 1) neurochemical specificity and 2)
neurovascular coupling independence. 1H fMRS is a direct in vivo measure of GLU (and
other metabolites). Neurochemical specificity of this approach provides insight not
possible using other neuroimaging approaches (e.g. fMRI). While not feasible in the
present study, future studies at higher field strength could leverage this approach to
examine task-related modulation of glutamine. It is estimated that ~80% of glutamine
molecules

are

directly involved

in

the

GLU-glutamine

cycle

(i.e.

excitatory

neurotransmission) (Gruetter, Seaquist, & Ugurbil, 2001; Lebon et al., 2002; Mason,
Petersen, De Graaf, Shulman, & Rothman, 2007; D. L. Rothman et al., 2012; Sibson et
al., 1997). Second, interpretation of the BOLD fMRI signal (most widely used in vivo
neuroimaging approach) is complicated by neurovascular coupling. For many research
questions, neurovascular coupling is not an insurmountable obstacle. However,
interpretation of BOLD signal from research studies that include older populations,
compare younger and older subjects, include subjects with cardiovascular confounds
(e.g. heart disease or chronic substance use), or use vasoactive pharmacological
challenges (e.g. this dissertation study) can be challenging. 1H fMRS is not confounded
by neurovascular coupling, and thus, presents an alternative approach to BOLD fMRI
for questions of task-related changes in brain function.
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5.2 Dissertation Results Discussion
5.2.1 Dissertation Results Overview
The overarching goals for this dissertation project were two-fold: 1) investigate
the effects of pharmacological stress manipulation on nicotine-seeking and selfadministration, and 2) investigate a plausible neurobiological mechanism by which
acute stress may potentiate

nicotine-seeking and self-administration. Results

demonstrated that the complex experimental design (within-subject, placebo-controlled,
double-blind, randomized cross-over design with multi-modal neuroimaging and
nicotine self-administration outcome variables) was feasible. Oral pretreatment with
pharmacological agents (YOH 54mg + HYD 10mg) significantly increased biomarkers
(BP, heart rate, saliva cortisol, and saliva α-amylase) of a physiological stress
response, relative to placebo (YOH 0mg + HYD 0mg). Experimental stress significantly
increased nicotine-seeking and self-administration (relative to placebo) among nontreatment-seeking cigarette smokers (controlling for nicotine dependence level [FTND]).
Multi-modal neuroimaging demonstrated that acute stress impaired dlPFC function and
task-related engagement – a plausible neurobiological mechanism of stress-potentiated
nicotine self-administration. In the remainder of this dissertation, results will be
interpreted, limitations and alternative explanations discussed, and treatment
implications described.
5.2.2 Stress and Relapse
As described in the Sections 2.2 and 2.3, ample evidence links experimental
stress and substance use relapse (or models of relapse). Preclinical studies reliably
demonstrated

that

pharmacological

agents

(e.g.

YOH)

reinstated

drug self-

administration behavior (model of relapse) across drugs of abuse (Ahmed & Koob,
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1997; Buczek et al., 1999; de Jong et al., 2009; Deroche et al., 1997; Erb et al., 2000;
Erb et al., 1996; Gass & Olive, 2007; Graf et al., 2013; Mantsch & Katz, 2007; Mantsch
et al., 2014; Mantsch et al., 2010; Shepard et al., 2004). Clinical treatment studies
indicated that self-reported stress was among the widely cited precipitants to substance
use relapse (M. al'Absi, 2006; Heishman, 1999; Hughes, 2009; Hymowitz et al., 1991;
Matheny & Weatherman, 1998). Further, individuals who reported high stress levels
during abstinence were more likely to relapse (Brewer et al., 1998; S. Cohen &
Lichtenstein, 1990). The central question of this dissertation study was simple: how
does acute stress influence brain function such that an abstinent individual is more
likely to relapse? However, it would be unethical to directly test this research question in
treatment-seeking smokers, who are actively attempting to quit. Rather, an approximate
ethical approach was used. Nicotine-seeking and self-administration among nontreatment-seeking individuals was measured during two identical experimental
sessions:

placebo and active stress.

Broadly, the literature described three

mechanisms through which acute stress may potentiate nicotine self-administration: 1)
impair dlPFC function and top-down executive control, 2) intensify aversive internal
states (e.g. negative affect, anxiety, etc.) that motivate relief via nicotine use, and 3)
increase appetitive motivation, nicotine salience or craving.
5.2.3 Dissertation Sample Characteristics
Self-reported

cigarette

smokers

were

recruited

locally

via

Craigslist

advertisements. Participants were screened twice for eligibility. Briefly, eligible
participants were young (21-35 yrs old), daily cigarette smokers (10+/day; FTND ≥ 4),
not currently using other substances (some marijuana and alcohol use was allowed),
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and without psychiatric, MRI, or cardiovascular contraindications. The modal participant
was 28 years old, male, and African-American. Participants reported smoking ~17
(primarily menthol) cigarettes per day, were moderately dependent (FTND ~ 6), and
averaged 13 years of formal education (Table 4.2).
5.2.4 Stress Potentiated Nicotine Self-Administration
Nicotine-seeking and self-administration behavior was measured via a choice
progressive ratio task. Participants were able to choose between two options (one puff
of their preferred brand of cigarette or money [$0.25]) across 11 choice trials, with
escalating response requirements for each successive unit earned. Participants were
able to earn any combination of either option, up to a maximum 11 units. Following
completion of the 30min task, participants smoked the exact number of cigarette puffs
earned on the choice task and inter-puff interval was timed. In this study, the number of
puff choices earned (and smoked) defined the extent of nicotine-seeking and selfadministration (i.e. direct measure of appetitive nicotine motivation). In addition, interpuff interval was a direct measure of nicotine self-administration rate (i.e. nicotine
consumption rate). Together, nicotine-seeking and self-administration behaviors reflect
nicotine motivation, but parsed into appetitive and consumptive phases, respectively.
Nicotine-seeking and self-administration behavior.

Results from this study

demonstrated that nicotine-seeking and self-administration during the placebo condition
were significantly positively correlated with nicotine dependence level (FTND;
accounted for 36% of the variance). This was not surprising. More heavily nicotine
dependent participants earned and smoked more cigarette puffs than those who were
less dependent. In the absence of an experimental manipulation, participants who
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smoked more outside of the laboratory chose to smoke more during the research study.
Therefore, FTND score was included as a covariate in outcome analyses. Controlling
for FTND, active stress significantly increased nicotine-seeking and self-administration
(i.e. appetitive nicotine motivation), relative to placebo. During the stress session,
nicotine self-administration was not correlated with nicotine dependence level (FTND
accounted for 1.1% of the variance). Relative to placebo, less dependent participants
(median split by FTND) increased, while more dependent participants decreased, their
nicotine-seeking and self-administration (~1.5 puffs and ~1 puff, respectively) during the
active stress session.
Nicotine consumption rate. As hypothesized, nicotine consumption rate (mean
inter-puff interval [s]) did not significantly differ as a function of active vs. placebo
stress. Limited number of observations and highly variable data across subjects may
have contributed to this non-significant finding. Nicotine dependence level (FTND) was
not related to nicotine consumption rate. Interestingly, our data indicate a differential
effect of acute stress on the appetitive and consumptive phases of nicotine motivation
which illustrate the specific effects of the stress manipulation.
In summary, relative to placebo, oral pretreatment with 54mg YOH and 10mg
HYD potentiated nicotine-seeking and self-administration, controlling for dependence
level. These findings were consistent with a priori hypotheses and prior research.
Further, these data validated this complex experimental model. Future studies can build
on this approach and evaluate medications that may blunt the effects of stress on
nicotine-seeking

and

self-administration.

The

effectiveness

of

FDA-indicated
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medications (e.g. varenicline) for smoking cessation may be enhanced by adjunctive
stress-blunting medications (e.g. prazosin).
5.2.5 Subjective and Physiological Effects
Physiological effects.

Oral pretreatment with YOH and HYD demonstrated

significant physiological effects, consistent with a stress response (Section 4.2.2).
Systolic and diastolic BP and HR exhibited significant Time X Dose interaction effects,
relative to the placebo session. Peak YOH+HYD effects increased systolic and diastolic
BP ~12 and ~7 mmHg and heart rate ~4 bpm relative to the placebo session. YOH and
HYD doses were administered such that physiological effects were apparent at the
onset of the MRI scan (1pm) and remained elevated throughout experimental
procedures (2+ hrs). Saliva cortisol levels exhibited a significant Time X Dose
interaction (biomarker of plasma cortisol levels; HYD administration). Saliva α-amylase
effects were less obvious and did not exhibit the hypothesized Time X Dose interaction.
Saliva α-amylase levels increased throughout the stress session (biomarker of plasma
noradrenaline levels; YOH administration), but not the placebo session. FTND score
was not related to any physiological effects.
The magnitude of the YOH+HYD-induced stress response was interpreted in the
context of other studies. Robust psychosocial stress-induction tasks (public speaking +
cognitive tasks) resulted in large effects on saliva cortisol, systolic BP, and HR (Section
4.2.3) (Dickerson & Kemeny, 2004; Ginty et al., 2014). Effect sizes from those studies
were comparable to those observed in this study. In summary, oral pretreatment with
YOH 54mg and HYD 10mg elicited a significant physiological stress response that
lasted 2+ hours (relative to placebo), comparable in magnitude to a robust psychosocial
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stressor. Physiological effects supported a priori hypotheses (less saliva α-amylase).
These data provided additional support that YOH+HYD is a valuable experimental
approach with methodological advantages compared to psychosocial stress-induction
techniques (reliable physiological stress response, placebo-control, double-blind
administration, dose-control, and sustained stress response [2+ hr]). Importantly, the
doses used herein were medically-safe and no adverse events occurred. Yet, despite
these methodological advantages, few human studies outside Dr. Greenwald’s
laboratory have investigated their effects in substance use disorders.
Subjective effects. Participants completed a battery of self-reported measures
periodically throughout each experimental session. The measures assessed general
internal states (anxiety and positive and negative affect) and nicotine-specific internal
states (withdrawal symptoms and relief-motivated and appetitive craving).
Nicotine-specific subjective effects. Self-reported nicotine withdrawal symptoms
were measured via the Minnesota Nicotine Withdrawal Scale (MNWS). Individuals
reported a significant increase in nicotine withdrawal across time within each session,
but withdrawal did not differ as a function of experimental session (active vs. placebo
stress). This was consistent with a priori hypotheses. Participants reported greater
nicotine withdrawal severity the longer they were unable to smoke (i.e. positive control),
but YOH+HYD did not modulate this effect. Similarly, appetitive and relief-motivated
craving (Brief Questionnaire of Smoking Urges; QSU) scores increased across time
within each session, but did not differ as a function of active vs. placebo stress.
Individuals craved cigarettes more the longer they abstained from smoking (i.e. positive
control of response consistency). We hypothesized that relief-motivated craving, but not
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appetitive craving, would increase more during the active stress session, relative to
placebo. In summary, there was no evidence from these subjective effects measures
that YOH+HYD enhanced nicotine withdrawal symptoms, appetitive craving, or reliefmotivated craving, relative to placebo.
These findings are relevant for substance use treatment. All three FDA-indicated
pharmacotherapies for smoking cessation (varenicline, bupropion, and nicotine
replacement products) target nicotine withdrawal and craving. However, as described in
Section 1.2, these medications (despite their effective attenuation of nicotine withdrawal
symptoms and craving) are associated with dismal long-term abstinence rates. Findings
presented herein indicate that acute stress does not potentiate nicotine-seeking and
self-administration via enhanced nicotine withdrawal or craving. Therefore, it is unlikely
that varenicline, bupropion, or nicotine replacement products would successfully
attenuate the effects of acute stress. Indeed, prior research demonstrated that
varenicline blocked smoking cue-induced craving, but not stress- plus cue-induced
craving (Ray et al., 2013). Bupropion increased physiological indices of stress reactivity
during acute smoking abstinence (Kotlyar et al., 2006). In addition, long term nicotine
use is associated with elevated circulating stress hormones and dysregulated stress
reactivity (Kreek & Koob, 1998; Wilkins et al., 1982). In summary, varenicline,
bupropion, and nicotine replacement products effectively attenuate nicotine withdrawal
and craving, but do not attenuate (rather, may enhance) an individual’s physiological
response to stress. Data presented herein suggested that acute stress does not act via
withdrawal or craving to potentiate nicotine-seeking and self-administration behavior.
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The effectiveness of FDA-indicated pharmacotherapies for smoking cessation may be
enhanced by adjunctive medications that blunt an individual’s stress response.
Alternative explanations. One alternative explanation is that participants did not
respond accurately or thoughtfully on these measures. Participant fatigue or disinterest
is possible as experimental sessions were long and repetitive. However, this is unlikely
because significant Time effects were found across experimental sessions. Results
demonstrated that participant withdrawal and craving increased as function of time
since last cigarette, as hypothesized (i.e. positive control). Moreover, this study was
powered to detect moderate effect sizes (not likely a statistical power issue).
General subjective effects.

Self-reported anxiety (STAI; state version)

decreased throughout each experimental session, but did not differ as a function of
active vs. placebo stress (Section 4.2.4). While significant, anxiety decreased an
average of ~5% from baseline levels. We attributed this effect to participant’s becoming
more comfortable as time elapsed during experimental sessions. Individuals may have
been slightly apprehensive about participation in a medical research study (especially
one that involved pharmacological dosing and an MRI scan). Self-reported affect (both
positive and negative) was measured via the Positive and Negative Affect scale
(PANAS). Participants reported a significant increase in negative affect throughout each
experimental session, but no effect of experimental session. Controlling for FTND,
positive affect decreased throughout each experimental session, but did not differ as a
function of active vs. placebo stress. FTND was not significantly related to anxiety or
negative affect. In summary, there is no evidence from this study that YOH+HYD
intensified aversive internal states, relative to placebo. These findings suggested that
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acute stress probably does not act via aversive internal states to potentiate nicotineseeking and self-administration.
Alternative explanations. As described above, this study was not under-powered
to detect effects. Participant apathy or boredom may have influenced these data
(possible with any subjective measure). However, participant responding was consistent
across experimental sessions (conducted at least 48 hrs apart) and within each
session. Finally, variable distributions approximated normality (or were corrected) at
each time point prior to statistical analyses. Thus, our observations do not suggest that
a few apathetic participants skewed these findings.
5.2.6 Neurochemistry Results
Voxel placement.

The AVP method was in-development when this project

launched subject recruitment. AVP was not used during the first six scans (14.3%;
manual placement), which resulted in poor geometric voxel overlap with the template
voxel (~62%; Figure 4.28 and Table 4.3). Voxel placement was assisted by AVP (e.g.
coordinate location was accurate, but rotation angles were incorrect or vice versa) in the
next 11 scans (~26%), which were associated with moderate accuracy (~75% overlap
with the template voxel). Finally, AVP prescribed the voxel location and rotation angles
for the remaining 25 scans (~60%) which had excellent accuracy (96% overlap with the
template voxel). Across all scans, mean voxel placement accuracy was very good for
this study (~86% overlap with the template voxel).
However, it is important to remember that 1H fMRS analyses were limited to
within-subject and within-session comparisons:

GLU levels during 2-back were

contrasted with rest separately for placebo and active stress. No between-subject or

125

between-session comparisons were analyzed. Therefore, voxel placement variability
across experimental sessions was more meaningful than voxel placement variability
across subjects. Mean between-session overlap within each subject (i.e. voxel
placement consistency across sessions) was very good (87% geometric overlap). To
provide context, 87% geometric voxel overlap is associated with ~1mm voxel placement
error during one scan. Mean voxel tissue composition for all scans was approximately
two-thirds white (~66%) and one-third gray (~32%) matter. In summary, AVP resulted in
excellent voxel placement accuracy and reliability. Overall, both between-subject and
between-session voxel overlap accuracy was very good (~86% and ~87%,
respectively).
Behavioral data.

Behavioral data demonstrated task compliance for both

experimental sessions (Section 4.2.7). Response accuracy during the letter 2-back
increased across task blocks during both experimental sessions (Time effect), but
accuracy improved more during the placebo session (Time X Dose interaction). On
average, participants responded significantly more accurately during placebo (~87%)
than active stress (~78%; Task effect). Response latency decreased across task blocks
for both sessions (i.e. task proficiency improved with repetition), but did not differ as a
function of active vs. placebo stress. In summary, response accuracy increased across
task blocks in both sessions (indicative of practice effects). As hypothesized,
YOH+HYD impaired 2-back response accuracy (relative to placebo), consistent with
prior research using a robust psychosocial stressor (Qin et al., 2009).

126

GLU modulation (32s resolution). LCModel fit and metabolite quantification was
100% automated. As described above, individual raw spectra were phase- and shiftcorrected prior to averaging and LCModel fit.
During the placebo session, GLU quantification at 32s resolution (8 avgs) was
reliable (Table 4.4) and importantly, LCModel fit characteristics did not differ as a
function of experimental task. GLU levels were significantly higher (2.7%) during 2-back
A relative to interleaved fixation-cross. Across task blocks, GLU levels were marginally
higher during 2-back A vs. rest (Task effect: p = .06). 2-back A GLU levels increased
(relative to rest) in later task blocks. GLU levels during 2-back B did not differ from
interleaved fixation-cross levels (p = .67). In general, GLU modulation (during 2-back A)
corresponded with 2-back response accuracy across task blocks (with the exception of
task block 2). The behavioral data demonstrated that participants performed poorly
during the first task block, but significantly improved with task repetition. During the first
task block, poor response accuracy was associated with virtually no GLU modulation
(i.e. limited dlPFC task engagement). Was poor task performance the cause of, or the
result of, limited dlPFC task engagement? Unfortunately, the answer is unknowable
from the present findings. Poor task accuracy and dlPFC engagement in the first task
block may have resulted from task complexity (resolved in later blocks; i.e. practice
effects) or the novel and distracting MRI environment (to which, participants
habituated). From task blocks 3 to 5, GLU modulation was apparent and steadily
increased which paralleled response accuracy. In summary, letter 2-back task
performance modulated GLU levels in the left dlPFC during the first 32s (2-back A), but
the effect was time-limited and not consistently found in the final 32s (2-back B) of task
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performance. Moreover, GLU modulation generally paralleled response accuracy
across task blocks. Findings during the placebo session in this study were consistent
with 1H fMRS pilot study results in healthy control subjects.
During the stress session, GLU levels did not differ as a function of task
performance (2-back A or B vs. interleaved fixation-cross rest; ps > .10). Moreover, two
LCModel fit characteristics differed as a function of experimental task (2-back vs.
interleaved fixation-cross rest): FWHM and SNR. SNR was higher and FWHM was
lower (more narrow spectral linewidth) during 2-back > rest. Importantly, these
differences did not translate into biased LCModel GLU fit uncertainty (GLU and
glutamine CRLB% did not differ as a function of experimental task). However, we
cannot rule out the possibility that these biases did not influence or confound GLU
quantification (Type II error is possible). Therefore a second analysis strategy was
used: 64s (16 avgs) moving average.
GLU modulation (64s resolution). Spectra from the 32s analyses were averaged
across task blocks: task block 1 data for 2-back A was averaged with task block 2 data
for 2-back A, and so on. This strategy was repeated for all task blocks and experimental
phases (2-back B and rest). This resulted in 4 time points for 2-back A, B, and rest. As
expected, 64s (16 avgs) resolution was associated with higher SNR and more reliable
LCModel fit. Relative to 32s resolution, SNR was ~5 points higher and GLU CRLB%
was at least 1% lower (with less variability).
During the placebo session, LCModel fit characteristics did not differ as a
function of experimental task for the placebo session (Table 4.5). A significant Time X
Task interaction indicated that GLU levels were higher during 2-back A relative to
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interleaved fixation-cross rest, but only in later task blocks. These results were similar to
the 32s resolution findings. Again, consistent with 32s resolution GLU findings, 2-back
B didn’t differ as a function of experimental task. Across four analytic strategies (and
two samples), findings presented herein repeatedly demonstrated that dlPFC GLU
levels were modulated during the first 32s of letter 2-back task performance (i.e. 2-back
A), but the effect was inconsistent and blunted during the final 32s of task performance.
There are two plausible explanations for these findings: 1) cognitive task switching or
directed attention modulated dlPFC GLU levels (and that effect was time-limited) or 2)
working memory performance modulated dlPFC GLU levels temporarily, but new steady
state levels were not established (i.e. habituation). Unfortunately, there was not
sufficient temporal resolution to disentangle these explanations. It should be noted that
this effect was contrary to a priori hypotheses. We hypothesized 2-back performance
would increase dlPFC GLU levels throughout the entire task block (i.e. establish new
steady state levels).
During the stress session, GLU levels were not modulated as a function of
experimental task (non-significant Task and Time X Task interaction effects). Further,
GLU levels during 2-back were generally lower than fixation-cross rest. Only one
LCModel fit characteristic differed as a function of experimental task for the 64s
resolution (SNR was higher during 2-back A than rest). However, a small difference in
SNR did not bias the certainty in the LCModel quantification of GLU or glutamine across
task phases (ps > .19).
In summary, this second analysis strategy corroborated initial findings at 32s
resolution and demonstrated, with more reliable LCModel fit, that 2-back performance
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modulated dlPFC GLU levels (relative to fixation-cross rest) during placebo, but not
active stress.
As described in Section 5.1.3 above, the

1

H fMRS signal is a direct

measurement of in vivo GLU molecules from all possible sources within the voxel.
Thus, results during the placebo session demonstrated that the number of GLU
molecules within the voxel location was higher during letter 2-back A relative to fixationcross rest. We interpreted these findings to indicate task-related cognitive demand
during 2-back increased neural and metabolic activity (and thus, GLU levels) in the left
dlPFC. These findings were consistent with the electrophysiology, 1H fMRS, fMRI BOLD
literature, and findings in the 1H fMRS pilot study.
Limitations and alternative explanations. All of the same limitations from the 1H
fMRS pilot study apply here. First, partial volume effects were possible. However, partial
volume effects were unlikely because the analysis strategy focused on within-subject
comparisons (GLU levels during task vs. rest) and voxel tissue composition variability
was low across experimental sessions (gray and white matter coefficient of variation
percentage was 10.5% and 7.2%, respectively). Second, AVP was associated with
accurate and reliable voxel placement. Voxel placement accuracy between-subjects for
this study was high (~86%). More importantly, within-subject voxel replacement
reliability (from the first to the second experimental session) was very good (~87%).
Third, due to SNR limitations, we were unable to reliably quantify other relevant
neurotransmitters (e.g. GABA and glutamine). Future studies could use higher field
strengths or different MRS sequences (e.g. MEGA-PRESS) to investigate task-related
modulation of GABA and glutamine levels.
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There are several alternative explanations for task-related GLU modulation. First,
the BOLD effect (i.e. FWHM) was nearly significant during the placebo session (p = .06)
and was significant during the stress session (p < .05). The BOLD effect may have
influenced metabolite quantification and T2*. However, LCModel should be immune to
the influence of linewidth on metabolite level quantification. Indeed, we found that NAA
levels did not differ as a function of task during either experimental session, which
suggested the BOLD effect did not bias NAA quantification. During the placebo session,
no metabolites differed as a function of experimental task other than GLU. However,
during stress, GPC+PC and Myo-Inositol did differ as a function of experimental task,
contrary to a priori hypotheses. Second, GLU’s transverse relaxation (T2*) could have
changed as a result of task performance. However, as described above, transverse
relaxation alone was unlikely to explain the observed increase in GLU signal during
placebo (Ogawa et al., 1992). Third, Type I error was possible for the placebo session.
However, evidence against this explanation was four-fold: 1) results were consistent
with the pilot study and the literature; 2) the experimental paradigm was designed to
minimize the possibility of Type I error (e.g. the use of a stabilization task [flashing
checkerboard], comparison to an interleaved fixation-cross rest condition, and reliable
voxel placement); 3) observed moderate effect size (i.e. study was not over-powered);
and 4) LCModel fit characteristics and metabolite levels (other than GLU) didn’t differ as
a function of experimental task. Fourth, Type II error was possible for the stress
session. LCModel fit characteristics (FWHM and SNR) significantly differed as a
function of experimental task during the stress session. However, these differences did
not influence uncertainty of LCModel GLU fit (GLU and glutamine CRLB% did not differ
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between 2-back vs. rest; 1H MRS glutamine peaks overlap with GLU at 3T). Moreover,
LCModel fit of GLU was reliable (GLU CRLB <7 ± <1%) across task and rest conditions.
Further, the FWHM bias (BOLD effect) did not influence the quantification of NAA
(which didn’t differ as a function of experimental task). Finally, overall GLU levels during
2-back tended to be lower (not higher) than interleaved fixation-cross levels.
Neurochemistry results summary. In summary, our findings indicated that letter
2-back task performance modulated GLU levels in the left dlPFC (relative to interleaved
fixation-cross rest) during the placebo, but not the active stress condition (consistent
with a priori hypotheses). These findings were consistent with the 1H fMRS pilot study.
As described in detail above, we interpreted task-related dlPFC GLU modulation to
reflect

increased

neural

and

metabolic

activity

associated

with

excitatory

neurotransmission driven by working memory task performance. We believe GLU
modulation is an in vivo biomarker of dlPFC engagement during working memory
performance. Importantly, 1H fMRS GLU levels, as a biomarker, are not confounded by
neurovascular coupling.
Extensive research at Yale University
demonstrated
performance

that
in

working

memory

task

non-human

primates

was

associated with increased neuronal spiking
frequency in the dlPFC (Goldman-Rakic, 1995).
As described in Sections 2.4.3 and 2.5.1,
persistent

excitatory

microcircuits

(glutamatergic) in cortical layer III are thought to

Figure 5.1: Noradrenaline Levels
and dlPFC Function. The inverted
‘U’
relationship
between
noradrenaline levels and dlPFC
function is depicted.
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maintain working memory traces during the ‘delay’ period (necessary for accurate
responding) (Wang et al., 2013). Using the same task paradigm and selective
pharmacological challenges, Arnsten and colleagues demonstrated that working
memory task performance and dlPFC neural spiking frequency exhibited an inverted
‘U’-shaped relationship with noradrenaline levels (Figure 5.1) (A. F. Arnsten, 2009).
Inadequate

α2-noradrenergic

receptor

stimulation

(i.e.

fatigue)

or

excessive

noradrenergic stimulation (i.e. stress) impaired working memory in non-human primates
(A. F. Arnsten, 2009). Synaptic noradrenaline has the highest binding affinity for α 2noradrenergic receptors and lower affinity for α1- and β1-noradrenergic receptors (A. F.
Arnsten, 2009). Thus, in the presence of excessive noradrenaline levels (i.e. stress),
noradrenaline molecules will ‘spill over’ and bind lower affinity α 1- or β1-noradrenergic
receptors, disrupt persistent excitatory microcircuits that maintain working memory
traces during the ‘delay’ period, and impair response accuracy (A. F. Arnsten, 2009).
YOH is a pre-synaptic α2-noradrenegeric antagonist that disinhibits presynaptic
noradrenergic release. The dose used in this study (oral pretreatment with 54mg of
YOH) significantly increased two biomarkers of a physiological stress response (BP and
saliva α-amylase; sympathetic ANS), relative to placebo. It is speculative, but plausible,
that YOH significantly elevated noradrenergic levels (stimulating lower affinity α 1- and/or
β1-noradrenergic receptors), which disrupted excitatory microcircuits in the dlPFC and
impaired 2-back task accuracy (shifting individuals to the right side of the downward
slope on the inverted ‘U’ in Figure 5.1). 1H fMRS data support this hypothesis. During
placebo, noradrenaline levels were ‘normal’ and response accuracy was high. 2-back
task performance significantly modulated GLU levels indicative of dlPFC engagement
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(consistent with non-human primate studies) (A. F. Arnsten, 2009). However, during the
active stress session, YOH+HYD significantly elevated BP and saliva α-amylase, which
was associated with attenuated GLU modulation (i.e. impaired dlPFC engagement) and
impaired response accuracy. These data support the hypothesis that acute stress
potentiates drug-seeking behavior via impaired top-down (specifically dlPFC) executive
function. Further, the present findings, in combination with the literature, provided
support that noradrenaline levels may be the culprit. Medications (e.g. prazosin [α 1adrenoreceptor antagonist] and propranolol [β1- and β2-adrenoreceptor antagonist]) that
block noradrenergic stimulation of lower affinity α1 and β1 receptors may rescue dlPFC
function. As described in Section 2.4.3, dlPFC function is associated with a host of
cognitive processes (e.g. delayed gratification, self-control, decision making, and goaldirected action) necessary for prolonged abstinence. Acute stress-compromised dlPFC
function could predispose an individual to habit-directed behavior (i.e. stimulusresponse; cigarette cue induced smoking relapse) or ill-prepared to adequately
suppress cigarette craving/withdrawal symptoms. Future studies should examine the
effects of prazosin and/or propranolol on dlPFC function and drug-seeking behavior
during acute experimental stress challenge.
The present dlPFC GLU modulation findings were buttressed by the rigorous
experimental design used:

within-subject, double-blind placebo-controlled, and

randomized cross-over design. All research subjects completed both experimental
sessions (which were identical) and typically within 7 days of one another (76% of
subjects). Further, all outcome analyses examined within-subject comparisons; thus,
each subject served as his/her own control.
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5.2.7 BOLD fMRI Results
Cerebrovascular reactivity (CVR). In the present study, neurovascular coupling
was a potential problem due to the use of a pharmacological challenge with known
vasoconstrictive properties. Thus, the breath-hold challenge task was implemented to
control for CVR differences. Briefly, participants were instructed (visually) to change
their breathing throughout the task across three phases:

uncontrolled (‘normal’)

breathing, paced breathing (3s in and 3s out), and breath hold (11s). Prior research
demonstrated a robust BOLD response during breath hold (relative to paced breathing)
(Bright & Murphy, 2013; Lipp et al., 2015; Magon et al., 2009; Murphy et al., 2011;
Sousa et al., 2014). Significant activation on this task reflected vascular effects (i.e.
non-neuronal) due to breath hold. As part of our fMRI analysis strategy, all betweensession (placebo vs. active stress) comparisons were CVR-corrected to reduce the
possibility of false positives due to the vascular effects of YOH+HYD.
Letter 2-back vs. fixation-cross rest.
compliance. Contrary to

Behavioral data demonstrated task

1

H fMRS behavioral data, response accuracy was non-

significantly higher during placebo vs. active stress (p = .11; 90% vs. 85%,
respectively). Data collection errors resulted in a substantial missing data (24%) for this
outcome variable and may have resulted in this comparison being under-powered. As
hypothesized, 2-back performance was associated with robust bilateral PFC activation,
relative to fixation-cross rest, during both experimental sessions (Figure 4.43; (Owen et
al., 2005)). However, contrary to a priori hypotheses, between-session comparisons
(CVR-corrected) revealed significantly more PFC activation during task performance (2back > rest) in the stress, relative to placebo, session (Figure 4.44). Even with the CVR-
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correction, we cannot rule out the possibility of YOH confounding these results. YOH
has robust vasoconstrictive effects that make interpretation of this finding challenging.
Within-session, task-evoked BOLD responses (i.e. 2-back > rest) are less confounded
and associated with a more straightforward interpretation.
Few studies have examined the effect of YOH on task-evoked BOLD responses
in human subjects. However, a number of studies have investigated the effects of
caffeine (another vasoconstrictive agent) on BOLD response. Unfortunately, these
studies provided little clarity for the unexpected BOLD findings in this study. In a wellcontrolled study among infrequent caffeine users, visual stimulation and finger-tapping
tasks evoked attenuated BOLD responses in the visual and motor cortices
(respectively) during caffeine (250mg oral dose), relative to placebo (Diukova et al.,
2012). Conversely, during visual and motor stimulation tasks, BOLD responses (in
another study) in visual and motor cortices (respectively) were amplified during
intravenous caffeine injection (2.5mg/kg), relative to saline (Chen & Parrish, 2009b).
Further, there was evidence that caffeine altered cerebral blood flow and cerebral
metabolic rate of oxygen in the visual cortex during visual stimulation, relative to
placebo (Chen & Parrish, 2009a; Griffeth, Perthen, & Buxton, 2011). Therefore, in
addition to the conflicting BOLD activation findings in the literature, the neurobiological
underpinnings of the BOLD signal may be altered by acute administration of a
vasoconstrictive agent. The present study did not measure other physiological indices
(e.g. cerebral blood flow, cerebral blood volume, oxygen metabolism) that may have
provided greater insight into these unexpected BOLD findings.
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The effects of caffeine on BOLD response in the PFC are more consistent, but
may be confounded by the cognitive-enhancing effects of caffeine. During an auditory
oddball task, caffeine was associated with greater task-evoked BOLD response in the
PFC, relative to placebo (Diukova et al., 2012). Similarly, during working memory task
performance, caffeine (100mg oral dose) amplified BOLD response in the PFC, relative
to placebo (Klaassen et al., 2013; Koppelstaetter et al., 2008). These findings were
consistent with the unexpected results observed herein during the letter 2-back
paradigm: amplified task-evoked BOLD response in the PFC during YOH+HYD. It is
possible that task-induced BOLD response exhibited regional differences due to
heterogeneous vasoconstrictive effects (vessel diameter or vascularization differences
in the PFC vs. visual/motor cortices). However, caffeine has known cognitive-enhancing
properties, while YOH+HYD tended to impair task performance, which further
complicated interpretation. Indeed, auditory oddball task performance was enhanced
during caffeine, relative to placebo (Diukova et al., 2012). In the working memory
studies, caffeine mostly did not alter working memory task performance (letter 2-back
and 3-, 4-, and 5-letter Sternberg accuracy were unaffected; 6-letter Sternberg accuracy
was impaired), relative to placebo (Klaassen et al., 2013; Koppelstaetter et al., 2008). In
summary, between-session interpretation of BOLD response data is complicated by the
vasoconstrictive properties of YOH. Interpretation of task-evoked BOLD within each
experimental session is more straightforward and provides greater clarity for neural
activation across brain regions during task performance.
Letter 2-back exploratory analyses.

Exploratory analyses examined task-

induced activation median split by nicotine dependence level (FTND). These analyses
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paralleled the significant Dose X FTND interaction effects on nicotine-seeking and selfadministration (Figure 4.45). Less nicotine dependent participants exhibited smaller
task-evoked BOLD response in the dlPFC in the stress (relative to placebo) session.
Conversely, more nicotine dependent individuals exhibited larger task-evoked BOLD
response in the dlPFC. These findings were consistent with the central tenet of this
research study: stress potentiated nicotine self-administration via impaired dlPFC taskengagement.
fMRI N-back smoking vs. neutral cued. Accuracy and response latency were
evaluated across levels of task difficulty (0-, 1-, and 2-back) and by image type
(smoking vs. neutral) for both experimental sessions.
Stress effects. Neutral images were associated with an N-back effect for both
the placebo and active stress sessions (as task difficulty increased, response accuracy
decreased; Figure 4.46). Interestingly, a similar effect was found for response latency:
across both sessions response latency decreased, as task difficulty increased (Figure
4.47). Smoking images were associated with an N-back X Dose interaction effect:
response accuracy decreased more as a function of task difficulty during placebo vs.
active stress. This effect may reflect that acute stress amplified smoking image
salience, which buoyed response accuracy. Similar to the findings with neutral images,
response latency decreased as task difficulty increased for smoking images (across
both experimental sessions).
Image effects.

During both experimental sessions, significant N-back effects

demonstrated that response accuracy decreased as task difficulty increased for both
image types (Figure 4.50 and 4.52). Response accuracy differed as a function of image
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type during the stress session (smoking > neutral images), but not the placebo session.
N-back X Image interaction indicated response accuracy decreased more for neutral
images than smoking images, as task difficulty increased. Response latency (for both
image types) decreased as task difficulty increased during the stress session, but not
the placebo session (p = .07; Figures 4.51 and 4.53). During both experimental
sessions, response latency decreased across N-back levels more for neutral images,
relative to smoking images. Main effects of image type were non-significant during
placebo and active stress.
Activation results. Following repeated substance use, drug-paired visual cues
become conditioned stimuli and elicit dopamine release in the nucleus accumbens
(without substance administration), consistent with anticipatory appetitive craving (N.
Volkow et al., 2009; N. D. Volkow et al., 2006, 2008). In fMRI studies of visual drug
cues, BOLD activation was often robust, but patterns varied across studies.
Consistently activated regions during drug cue exposure fMRI studies were: amygdala,
mOFC/mPFC, dlPFC, and ventral and dorsal striatum (Chase et al., 2011; Engelmann
et al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Methodological factors, such
as treatment status (out-of-treatment individuals show more robust activation), time
since last cigarette (acute abstinence enhanced cue reactivity), and temporal delay until
next smoking opportunity (immediate smoking opportunities were associated with more
robust activation) influence BOLD fMRI results (Jasinska et al., 2014; Wilson et al.,
2005). These factors were considered in the design of the present study. Nontreatment-seeking smokers, in acute abstinence at the time of fMRI BOLD data
collection (~2hr since paced puff procedure), were reminded they would have an

139

opportunity to smoke following the MRI scan. fMRI activation analyses focused on the
effect of image type (smoking > neutral) across N-back levels (0-, 1-, and 2-back) and
compared the relative task-evoked BOLD response between experimental sessions.
Across N-back levels, smoking (> neutral) images elicited greater BOLD response in
‘reward’-associated brain regions during placebo, compared to active stress. These
findings were contrary to a priori hypotheses. During 0- and 1-back (while response
accuracy was high and didn’t differ by image type), greater BOLD activation was
observed in the ventral and dorsal striatum, mPFC, mOFC, and amygdala during
placebo, relative to stress.
Activation in the ventral striatum is associated with drug craving, appetitive
motivation, and encompasses the ‘final common pathway’ of addictive behaviors (Rita Z
Goldstein & Volkow, 2002; R. Z. Goldstein & Volkow, 2011; Peter W Kalivas & Volkow,
2005; G. F. Koob & Volkow, 2010; N. Volkow et al., 2009). Amygdala activation is
associated with the emotional salience of drug cue (Chase et al., 2011; Engelmann et
al., 2012; Kühn & Gallinat, 2011; Wilson et al., 2004). Activation in the dorsal striatum
may indicate mental rehearsal of habitual or ‘over-learned’ behaviors (e.g. smoking) (L.
Schwabe, Joels, et al., 2012; L. Schwabe et al., 2010; L. Schwabe & Wolf, 2011).
mOFC and mPFC activation may reflect reward appraisal, anticipation, or drug cue
salience (Chase et al., 2011; Hayashi et al., 2013; Wilson et al., 2004).
At the 2-back level, response accuracy differed as a function of image type
(smoking > neutral) and experimental session (stress > placebo). Behavioral proficiency
differences complicated interpretation of the BOLD activation patterns. Generally,
activation was diminished during 2-back task performance during both experimental
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sessions. This was not unexpected; 2-back task performance demanded greater
attentional focus, which may have minimized the salience of smoking images. Sporadic
clusters were observed in the amygdala, ventral striatum, mOFC, and vlPFC during the
placebo session. During stress, three clusters were found: mOFC, dorsal striatum, and
dorsal PFC. Direct comparisons of experimental sessions (CVR-corrected; stress vs.
placebo) across all N-back levels revealed robust BOLD activation differences. As
described above, the vasoconstrictive properties of YOH may confound interpretation of
direct between-session comparisons, but are presented here for continuity and
transparency. ‘Reward’-region activation was much greater during placebo, relative to
active stress. Large clusters were found in the amygdala, ventral and dorsal striatum,
mOFC, mPFC, dACC, vlPFC, superior parietal lobule, and dlPFC during placebo (>
stress). These findings may reflect enhanced cue salience and appetitive motivation
during placebo. Conversely, only one cluster was found in the mOFC for stress (>
placebo). These neural activation patterns suggest that stress attenuated smoking cueevoked BOLD activation, relative to placebo. These findings were contrary to a priori
hypotheses and inconsistent with subjective effects (nicotine withdrawal and craving) as
well as, nicotine-seeking and self-administration results. These findings do not support
the idea that stress potentiated nicotine-seeking and self-administration via amplified
‘bottom-up’ signaling (e.g. enhanced smoking cue salience or appetitive motivation).
5.2.8 fMRI vs. 1H fMRS
Exploratory analyses examined the statistical relationship between BOLD fMRI
response and 1H fMRS GLU levels during letter 2-back (> fixation-cross rest). These
tasks were performed sequentially (1H fMRS always preceded fMRI), but task
parameters were identical. The 1H fMRS voxel for each subject was used as a mask for
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fMRI contrasts, from which Z scores (peak activation) and peak cluster extents were
extracted, for the initial 32s and final 32s of task performance (2-back A and B,
respectively). The first fMRS task block was ignored (allow response accuracy to
stabilize; practice effects). Thus, the analysis space consisted of two bivariate
correlation matrices (Z score and cluster extents) with 32 cells (four rows of fMRI
metrics [2-back A and B X 2 task repetitions] by 8 columns of fMRS metrics [2-back A
and B X 4 task repetitions]) for the placebo and active stress sessions. Seven of 32
cells (21.9%) were positively correlated for fMRI Z scores and 5 of 32 cells (15.6%)
were positively correlated for fMRI cluster extents during the placebo session. During
the stress session, 1 cell (3.1%) was negatively correlated for fMRI Z scores and none
were correlated for fMRI cluster extents. Thus, letter 2-back task performance was
associated with moderate statistical coherence within subjects across neuroimaging
metrics (fMRI BOLD and 1H fMRS GLU) during the placebo session, and virtually no
coherence during the active stress session. These exploratory findings emphasized the
discrepant effects of stress on neuroimaging biomarkers of dlPFC task-engagement
(YOH+HYD amplified BOLD activation, but attenuated GLU modulation during letter 2back), and highlighted the importance of considering YOH’s vasoconstrictive effects on
BOLD response.
5.3 Overall Summary
The three primary goals of the 1H fMRS pilot study were to: 1) develop and
evaluate the AVP method for voxel placement, 2) develop a working memory 1H fMRS
paradigm, and 3) quantify dlPFC GLU modulation during working memory task
performance. Results from the pilot study demonstrated that the AVP method was
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feasible, reliable, and accurate. This novel method for automated voxel placement is
publicly available (free-of-charge) for download. AVP was developed to be flexible such
that it can be used across single voxel neuroimaging studies, regardless of: subject
population, anatomical region, MRI scanner system, and field strength. Results from the
1

H fMRS pilot study (N = 16) demonstrated that 2-back task performance modulated

dlPFC GLU levels relative to continuous and interleaved fixation-cross rest. 2-back A
GLU levels were ~3% higher than rest. Importantly, LCModel fit characteristics did not
differ as a function of experimental task and metabolites other than GLU were not
modulated during 2-back A performance. Results during 2-back B were mixed and
complicated by significant task-related modulation of Myo-Inositol and NAA. Working
memory task-related GLU modulation in the dlPFC likely reflected increased metabolic
activity driven by cognitive task engagement. In summary, the 1H fMRS pilot study
validated a novel in vivo biomarker of dlPFC task-engagement that is not confounded
by vascular effects.
The two primary goals for the dissertation study were to:

1) investigate the

effects of pharmacological stress manipulation on nicotine-seeking and selfadministration and 2) investigate a neurobiological mechanism through which acute
stress may potentiate nicotine self-administration. Self-reported cigarette smokers were
screened for psychiatric, cognitive, MRI and cardiovascular contraindications.
Participants (N = 21) completed two identical oral-dosing experimental sessions: active
(YOH 54mg + HYD 10mg) and placebo stress (YOH 0mg + HYD 0mg). A rigorous
experimental design was used: within-subject, placebo-controlled, double-blind, and
randomized cross-over design. Active pharmacological stress increased biomarkers of
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a physiological stress response (BP, HR, saliva cortisol and α-amylase) throughout
experimental procedures (2+ hrs), relative to placebo. Active stress (relative to placebo)
potentiated

nicotine-seeking

and

self-administration

(controlling

for

nicotine

dependence level [FTND]) on an 11-trial choice progressive ratio task (30min). Stress
did not alter nicotine consumption rate (inter-puff interval). These findings were
consistent with a priori hypotheses and validated the experimental model used herein.
Nicotine withdrawal, cigarette craving, and negative affect increased throughout each
session (as length of experimental abstinence increased), but were not altered as a
function of active vs. placebo stress (contrary to a priori hypotheses). Similarly, anxiety
and positive affect decreased throughout each experimental session, but were not
differentially affected by active vs. placebo stress. Consistent with the 1H fMRS pilot
study, working memory task performance modulated GLU levels in the left dlPFC during
the placebo session. GLU levels were 2.7% higher during the first 32s of letter 2-back
task performance relative to interleaved fixation-cross rest. During the stress session,
GLU levels did not differ as a function of 2-back performance. Behavioral data
demonstrated that participants’ responded significantly more accurately during placebo,
relative to active stress. These results were consistent with a priori hypotheses and
extensive non-human primate research. During both placebo and active stress, letter 2back performance evoked significant bilateral BOLD response. Inconsistent with a priori
hypotheses, BOLD response in the dlPFC was greater during stress, relative to
placebo. However, YOH is vasoconstrictive, which may have confounded betweensession BOLD comparisons. Smoking-related and neutral images were yoked with
letter

N-back

to

investigate

smoking

cue-evoked

BOLD

response.

Results
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demonstrated that smoking-related (> neutral) images elicited greater BOLD response
in ‘reward’-associated brain regions during placebo, relative to active stress. Across Nback levels, activation was consistently observed in the mOFC, mPFC, ventral striatum,
amygdala, and PFC during placebo, but not active stress. Activation in ‘reward’associated brain regions may reflect the salience of visual smoking cues or cue-elicited
appetitive motivation.
Taken together, results from this study suggest that acute experimental stress
(relative to placebo) elicited a robust physiological stress response, potentiated
nicotine-seeking and self-administration, impaired dlPFC function, attenuated dlPFC
task-related engagement, and suppressed ‘reward’ region BOLD response to visual
smoking cues among non-treatment-seeking cigarette smokers. These findings provide
empirical support for a plausible neurobiological mechanism. Acute stress may have
potentiated nicotine-seeking and self-administration via impaired dlPFC function and
attenuated task-related engagement. It is speculative, but plausible, that excessive
noradrenergic stimulation mediated the effect of stress on dlPFC function. In summary,
data presented herein support the theory that acute stress may act via a ‘top-down’
mechanism to precipitate substance use relapse. There was no evidence from this
study that acute stress amplified ‘bottom-up’ signals (withdrawal, craving, aversive
internal state, or visual smoking cue salience) to increase nicotine-seeking and selfadministration. Future studies will investigate dose-response relationships and
pharmacological agents (e.g. prazosin and propranolol) that may blunt the effects of
acute stress on dlPFC function and nicotine-seeking and self-administration.
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Nicotine use, especially cigarette smoking, is a significant public health problem.
Existing pharmacotherapies attenuate nicotine craving and withdrawal symptoms.
However, the majority of patients relapse within the first year of treatment. Treatment
studies indicate a commonly cited precipitant to smoking relapse is stress.
Pharmacotherapies do not attenuate, and may exacerbate, the effects of acute stress.
Experimental studies (preclinical and clinical) indicate that acute stress potentiates
drug-seeking behavior across drugs of abuse. Despite a robust literature linking acute
stress and substance use, neurobiological mechanisms remain poorly understood. A
more complete understanding of the neurobiological effects of acute stress on brain
function may facilitate development of novel interventions. Adjunctive stress-blunting
medications may improve the effectiveness of existing pharmacotherapies.
The present study investigated the effects of pharmacological stress-induction
among cigarette smokers. Non-treatment-seeking cigarette smokers were recruited
locally and screened for psychiatric, medical, and neuroimaging contraindications.
Using a double-blind, placebo-controlled within-subject random cross-over design,
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participants (N = 21) completed two oral-dosing experimental sessions: active
(yohimbine [YOH] 54mg + hydrocortisone [HYD] 10mg) and placebo (YOH 0mg + HYD
0mg) stress. Prior research indicated that YOH+HYD is a robust pharmacological
stress-induction technique that stimulates the Autonomic Nervous System (ANS) and
Hypothalamic-Pituitary-Adrenal (HPA) axis systems, increases circulating levels of
noradrenaline and cortisol (two primary stress hormones), and potentiates drug-seeking
behavior. Throughout each experimental session, subjective and physiological effects
were measured. In addition, participants completed a 60min magnetic resonance
imaging (MRI) scan which consisted of three task paradigms: 1) letter 2-back, 2)
smoking cued letter N-back, and 3) breath-hold challenge. Participants completed a
working memory paradigm (letter 2-back) during proton functional magnetic resonance
spectroscopy (1H fMRS). Left dorsolateral prefrontal cortex (dlPFC) neurochemistry was
evaluated during letter 2-back task performance. Next, participants completed a cued
N-back paradigm that consisted of images (cigarette smoking or neutral) centered
behind capitalized letters across three levels of N-back task difficulty: 0-, 1-, and 2back. Finally, participants were instructed (visually) to control their breathing across
three phases:

‘normal’ breathing, paced breathing (3s in/3s out), and breath-hold

challenge (11s). After the MRI scan, participants completed a choice progressive ratio
task. Across 11 independent choice trials, participants could earn one cigarette puff
(preferred brand) or money ($0.25) via behavioral responding. Each successive unit
earned (puffs or money, independently) was associated with a higher response
requirement (progressive ratio schedule). At the end of the 30min task, participants
smoked the exact number of cigarette puffs earned and/or were provided the amount of
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money earned. Number of puffs earned and smoked was a direct measure of nicotineseeking and self-administration behavior (nicotine motivation). Participants were
compensated for their time.
Results indicated that oral pretreatment with YOH+HYD increased biomarkers of
a physiological stress response: systolic and diastolic blood pressure, heart rate, saliva
cortisol and α-amylase (indirect biomarker of noradrenaline levels), relative to placebo.
YOH+HYD potentiated nicotine-seeking and self-administration behavior (controlling for
nicotine dependence level), relative to placebo. Appetitive and relief-motivated cigarette
craving, nicotine withdrawal symptoms, negative affect, and anxiety levels increased
throughout each session, but did not differ by experimental session (active vs. placebo
stress). Similarly, positive affect decreased throughout each session, but did not as a
function of stress. 1H fMRS indicated that letter 2-back performance increased left
dlPFC glutamate (GLU) levels relative to interleaved fixation cross rest (indicative of
task engagement) during the placebo, but not active stress, session. Further,
YOH+HYD impaired letter 2-back response accuracy, relative to placebo. Across Nback levels (0-, 1-, and 2-back), fMRI indicated more robust neural activation across
‘reward’-associated brain regions in response to smoking images (> neutral images)
during placebo, relative to active stress.
Results demonstrated YOH+HYD induced a sustained physiological stress
response (ANS and HPA axis) and potentiated nicotine-seeking and self-administration.
YOH+HYD attenuated dlPFC task engagement and impaired response accuracy during
a well-established working memory task. These findings provide experimental support
for a plausible neurobiological mechanism through which acute stress may potentiate
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nicotine self-administration. Acute stress-impaired dlPFC function may potentiate
nicotine self-administration and, among abstinence-motivated individuals, precipitate
smoking relapse. Prior research demonstrated dlPFC function is associated with a host
of cognitive processes (e.g. delayed gratification, self-control, decision making, etc.)
associated with prolonged smoking abstinence. Future studies are needed to confirm
this hypothesis, investigate dose-response relationships, and evaluate the efficacy of
stress-blunting medications in combination with existing pharmacotherapies for smoking
cessation.
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AUTOBIOGRAPHICAL STATEMENT
“If we knew what we were doing, it would not be called research, would it?”
-Albert Einstein

